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"Anybody who has been seriously engaged in scientific work 
of any kind realizes that over the entrance to the gates of the 
temple of science are written the words: ‘Ye must have faith’. 
It is a quality which the scientist cannot dispense with."  
Max Planck, 1932 
 
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1. SUMMARY 
 
The general aim of the present thesis was to investigate the role of sleep in the recovery 
process of the brain after ischemic stroke in rats, and in particular to understand 
whether sleep promotion could improve post-stroke recovery. 
Sleep-wake disturbances have been described in patients suffering from stroke 
and appear to have a negative impact on rehabilitation and long-term outcomes. In the 
experimental stroke model, sleep disruption has detrimental effects on infarct size, 
expression of plasticity-related genes, and functional recovery, while sleep stimulant 
gamma-hydroxybutyrate (GHB) accelerates stroke recovery in mice. Yet, the role of 
sleep and its underlying mechanisms in modulating the injured brain and clinical 
outcomes are poorly known. Promotion of neuroplasticity during recovery may 
represent an effective therapeutic strategy and, since sleep has been implicated in 
facilitation of neuroplasticity, approaches targeting sleep may lead to development of 
treatment able to improve long-term functional outcome after stroke. 
The first goal was to evaluate whether two pharmacological agents, baclofen 
(Bac) and GHB would induce a physiological sleep in rats. Recently, a lot of effort have 
been put to create drugs acting through GABA receptors in order to promote 
physiological sleep for therapeutic purposes. Both drugs, which act through GABAB 
receptors, have been shown to promote sleep in humans, but their effects in rodents 
remain unclear. The results of this study demonstrated that Bac and GHB induced a non-
physiological state characterised by atypical behaviour and abnormal 
electroencephalogram (EEG) pattern, and affected vigilance in rats. However, the 
principal finding was that Bac, but not GHB, had sleep-promoting properties (facilitated 
and consolidated sleep). Therefore, as the next step we decided to use Bac as a sleep-
promoting drug and evaluate effects on functional recovery after stroke. 
The second study aimed at investigating stroke outcome following repeated 
treatment with Bac in a rat model of focal cerebral ischemia. The first injections of Bac 
or saline were given 24 h after initiation of ischemia and then twice daily for 10 
consecutive days. The data demonstrated that repeated Bac treatment after stroke 
affected sleep, neuroplasticity and motor function but not the size of the brain damage. 
Thus, Bac administration increased non-rapid eye movement (NREM) sleep amount and 
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improved motor function recovery concomitantly with enhanced axonal sprouting and 
neurogenesis. Furthermore, although Bac had no effect on the size of the lesion volume, 
it reduced atrophy of the corpus callosum. These results indicate that delayed repeated 
Bac treatment promotes neuronal plasticity after stroke and thereby benefits motor 
function recovery. We suggest that observed effects might be mediated by sleep, 
emphasizing the importance of sleep in recovery processes. 
In summary, the results of this work contribute to the understanding of the sleep-
modulating effects on stroke recovery processes, indicating that pharmacological sleep 
promotion could mediate and enhance endogenous recovery mechanisms in a rat model 
of focal cerebral ischemia. Furthermore, these studies not only advance our knowledge 
in basic principles of sleep function in the injured brain but may also offer a rationale for 
a novel strategy to promote recovery after stroke, and possibly other brain injuries, by 
developing sleep-modulating treatments. 
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2. ZUSAMMENFASSUNG 
 
Das Ziel der vorliegenden Arbeit war es die Rolle von Schlaf in Bezug auf den 
Genesungsprozess des Gehirns nach einem ischämischen Schlaganfall bei der Ratte zu 
untersuchen. Im Fokus stand die Frage, ob Schlafförderung einen Einfluss auf eine 
verbesserte Genesung nach einem Schlaganfall haben könnte. 
Bei Patienten nach einem Schlaganfall wurden Störungen des Schlaf-Wach-
Verhaltens beschrieben. Diese scheinen negative Auswirkungen auf die Rehabilitation 
und das Langzeitergebnis zu haben. Im experimentellen Ansatz für Hirninfarkte führen 
Schlafstörungen einerseits zu nachteiligen und schädlichen Effekten in Bezug auf 
Infarktgrösse, Expression von Plastizitäts-relevanten Genen und die funktionelle 
Genesung, andererseits führt eine Schlafförderung, eingeleitet durch das Stimulanz 
Gamma-Hydroxybutyrat (GHB), zu einer beschleunigten Regeneration bei Mäusen. 
Dennoch ist die Rolle von Schlaf und den dahinter stehenden Mechanismen, welche für 
die Modulierung des verletzten Gehirns und das klinische Ergebnis verantwortlich sind, 
bislang nur ungenügend untersucht. Die Förderung der Neuroplastizität während der 
Genesung könnte eine effektive therapeutische Strategie darstellen. Zudem könnte ein 
Ansatz, mit  Fokus auf den Schlaf, zu einer neuen Behandlung führen, welche einen 
positiven Einfluss auf das funktionelle Langzeit Ergebnis nach einem Hirnschlag hätte. 
Dies vor allem im Hinblick darauf, dass der positive Einfluss von Schlaf auf die 
Begünstigung der Neuroplastizität bereits belegt wurde. 
Der erste Teil der hier vorliegenden Arbeit, war die Evaluierung zweier 
Medikament, Baclofen (Bac) und GHB, hinsichtlich ihres Einflusses auf die 
physiologische Schlafförderung bei Ratten. Kürzlich wurden Bemühungen intensiviert, 
Medikamente zu therapeutischen Zwecken zu untersuchen, welche über den GABA 
Rezeptor agieren und dadurch den physiologischen Schlaf beeinflussen. Bei beiden 
Medikamenten, welche über den GABAB Rezeptor wirken, wurde eine Schlafförderung 
beim Menschen nachgewiesen. Deren Einfluss auf Nager ist jedoch unbekannt. Die 
Ergebnisse der hier vorliegenden Studie haben gezeigt, dass sowohl Bac als auch GHB 
einen nicht-physiologischen Zustand einleiteten, welcher charakterisiert wird durch 
atypisches Verhalten, abnormale Elektroencephalogram (EEG) Aktivität und einen 
Einfluss auf die Wachsamkeit der Ratten. Zusätzlich aber zeigten die Resultate die 
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schlaffördernde Wirksamkeit (erleichternd und konsolidierend) von Bac jedoch nicht 
von GHB. Daher wurde Bac als schlafförderndes Mittel zur Evaluierung der Effekte auf 
die funktionelle Genesung nach einem Schlaganfall gewählt. 
Der zweite Teil dieser Arbeit befasst sich mit der Untersuchung des Einflusses 
der wiederholten Gabe von Bac auf den Ausgang einer fokalen zerebralen Ischämie im 
Rattenmodell. Erste Injektionen von Bac oder Saline erfolgten 24 Stunden nach 
Initiation der Ischämie und jeweils zwei Mal täglich an den darauffolgenden 10 Tagen. 
Die Daten ergaben, dass eine Bac Behandlung den Schlaf, die Neuroplastizität und auch 
die motorischen Funktionen beeinflusst, jedoch keinen Einfluss auf die Grösse der 
geschädigten Hirnregion hat. Daraus lässt sich schliessen, dass die Bac Gabe eine 
Zunahme des Non-Rapid Eye Movement (NREM) Schlafes als auch eine verbesserte 
Regeneration der motorischen Funktionen nach sich zieht. Diese wurden von einem 
verstärkten axonalem Sprouting und Neurogenese begleitet. Die Resultate zeigten 
ebenso, dass obwohl Bac keinen Effekt auf die Grösse des Läsionsvolumens hatte, es die 
Atrophie im Corpus callosum reduzierte. Diese Daten indizieren, dass eine verzögerte 
und wiederholte Behandlung mit Bac die neuronale Plastizität nach einem Schlaganfall 
fördert und dadurch zu einer verbesserten Regeneration der motorischen Funktionen 
führt. Wir vermuten, dass die beobachteten Effekte durch Schlaf vermittelt werden und 
unterstreichen dadurch die Wichtigkeit des Schlafes im Regenerationsprozess.  
Zusammenfassend tragen die Ergebnisse dieser Arbeit zum Verständnis der 
Schlaf-modulierenden Effekte auf die Regenerationsprozesse nach einem Schlaganfall 
bei. Sie weisen darauf hin, dass pharmakologische Schlafbeeinflussung endogene 
Regenerationsmechanismen im Rattenmodell der fokalen zerebralen Ischämie auslösen 
oder verstärken kann. Des Weiteren, führen die in dieser Arbeit vorgestellten 
Ergebnisse nicht nur zum näheren Verständnis der grundlegenden Mechanismen der 
Schlaffunktion im geschädigten Gehirn, sondern bieten auch ein Prinzip für eine 
neuartige Strategie zur Förderung der Genesung nach einem Schlaganfall und, 
möglicherweise, auch anderer Gehirnverletzungen, durch die Entwicklung neuer Schlaf-
modulierender Behandlungen. 
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3. INTRODUCTION 
 
3.1 Stroke  
 
Basic pathophysiology and current treatments 
“If one desired to guarantee the failure of a drug in clinical trials then one should 
develop a compound for the treatment of stroke”. Although that comment was made in 
early 1980s by a notable neurosurgeon, it continues to be held by many clinicians and 
people in pharmaceutical industry. The reason for this ongoing pessimism is that, beside 
thrombolysis, there are still no drugs which could be given to stroke patients soon after 
the onset of symptoms to minimize the subsequent neurological problems and to 
improve functional recovery. 
Stroke still remains the leading cause of chronic adult disability and the third 
leading cause of death in major industrialized countries, behind heart disease and  
cancer (Duncan, 2002, Burns et al., 2009). There are two major types of stroke: ischemic 
and hemorrhagic. The most frequent is ischemic stroke, which results from an occlusion 
by thrombus or embolus of a cerebral artery. This leads to a reduction in the brain blood 
flow, and to a major decrase in the supply of oxygen and glucose in the affected regions. 
Neurons that are deprived of their normal metabolic substrates cease to function in 
seconds and show signs of structural damage within few minutes (Dirnagl et al., 1999). 
Neuronal death consequently leads to damage in functional networks and to impairment 
of sensation, movement or cognition. Ischemic strokes are often associated with 
disorders that involve clotting of the blood or arterial inflammation. Hemorrhagic stroke 
is instead caused by intracerebral bleeding (within the brain tissue) or subarachnoid 
hemorrhage. Hemorrhagic stroke is usually linked to disorders, which prevent or reduce 
normal blood clotting, and which therefore result in an increased potential for bleeding. 
Moreover, it could be associated with blood vessels malformations, such as weakness, 
causing a bulge of the walls known as aneurysms. Even though approximately 75% 
people survive their initial stroke, just one third of them recover completely. According 
to the World Health Organization (Organization., 2007) 15 million people suffer stroke 
worldwide each year. Of these, five million die and another five million remain 
permanently disabled. This long-term disability implies that the majority of the costs 
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related to stroke is consumed on the support of stroke survivors, the number of whom is 
expected to keep growing due to the natural aging of the population. For these reasons 
stroke is, and will continue to be one of the most challenging neurological diseases. 
Therefore, substantial advances in prevention and treatment of stroke are of principal 
importance. 
Despite increasing knowledge about mechanisms occurring in the brain after 
ischemic injury effective treatments available for stroke patients are still lacking. So far, 
the only therapy that has been approved for clinical use is the administration of 
recombinant tissue plasminogen activator (rt-PA) which by lysing embolus or thrombus, 
restores the blood flow in the compromised brain region and therefore protects 
damaged ischemic cells from death. The area of the most drastic blood flow reduction 
(the ischemic core) is surrounded by the area of potentially salvageable tissue and 
partially preserved metabolism. This area, called ischemic penumbra, is compromised 
by the low blood flow, but can be protected either by reflow or by administration of 
neuroprotectants. Although thrombolysis is clinically effective in treating acute ischemic 
stroke (1995), its utilization is currently very low and limited by several factors. Because 
of the narrow therapeutic time window (rt-PA must be given within 4.5 h of symptoms 
onset), it can be used to treat a very small proportion (less than 10%) of the stroke 
victims evaluated in the emergency room. Moreover, not all of the patients qualify for 
and benefit from thrombolysis (1995, Hacke et al., 2008, Ahmed et al., 2010), as it might 
increase the risk of symptomatic intracranial hemorrhage (Zhang et al., 2012). The 
second major approach in the research of treatment for ischemic stroke is enhancing 
neuroprotection in order to salvage the brain tissue in the penumbra. A possible way to 
achieve that is by the use of drugs that interfere with the mechanisms of the ‘ischemic 
cascade’ and block the pathological processes, minimizing the subsequent 
neurodegeneration (Dirnagl et al., 1999). Without such an intervention the cells in the 
penumbra will die and the ischemic core will expand (Fig. 3.1.1). Clinical trials 
evaluating neuroprotective drugs for stroke were initiated in the 1980s and are still in 
the progress (Auriel and Bornstein, 2010). However, after decades of research and a 
multitude of neuroprotective compounds, which were promising in animal models of 
stroke, no drug was proven beneficial to stroke recovery in the clinical trial phase 
(Green and Shuaib, 2006, Ginsberg, 2009, Auriel and Bornstein, 2010). These 
dissapointing results suggest that, in stroke patients, improving neuroprotection might 
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not be as straightforward as it is in the experimental models. This raised an uncertainty 
about this type of therapeutic strategy alone in treating stroke patients and reducing 
neurological deficits. Therefore, development of new approaches for ischemic stroke 
therapies has become crucial.  
 
                      
Fig. 3.1.1 An occlusion of a branch of the middle cerebral artery.  
The middle cerebral artery has an indication of the ischemic core area and the penumbra. The figure 
shows the spread of damage as occurs with and without neuroprotective drug administration 
(redrawn from (Green and Shuaib, 2006)). 
 
 
In search of new treatments, numerous neurorestorative therapies such as 
transcranial magnetical stimulation (TMS) (Talelli and Rothwell, 2006, Hallett, 2007), 
transcranial direct current stimulation (tDCS) (Hummel and Cohen, 2006), cell-based 
and pharmocological therapies (Zhang and Chopp, 2013) are currently being 
investigated. The main approach of restorative therapies is to support and stimulate 
brain repair processes during the subacute and chronic phases after insult, with the aim 
of improving functional recovery (Cramer, 2008, Zhang and Chopp, 2013).  
“Since regeneration of transectioned central axons has never been convincingly 
demonstrated in higher mammals, it seems in most instances that one must resort to the 
assumption that intact fibers take over for the damaged ones.” (Brodal, 1973). This 
statement written in 1973 by Alf Brodal, based on his own experience after stroke, has 
appeared to be indeed the case. Although brain damage after ischemic injury can be 
devastating, a certain spontaneous degree of restoration of sensorimotor functions 
occurs both in humans and animal models (Murphy and Corbett, 2009, Johansson, 
 2011). Loss of function attributable to stroke is partly due to neuronal death in the 
infarcted tissue but it is also a result of cell dysfunction in the areas surrounding
infarct. These areas encompass the part of the underperfused penumbra, the non
ischemic peri-infarct tissue and remote (including contralateral) brain areas that are 
connected to the area of tissue damage 
neurological deficits reflect injury to the core as well as the penumbra (Fig. 3.1.2). As 
collateral perfusion develops, brain function c
(Furlan et al., 1996). However
recruit parts of the ischemic penumbra into infarction. Thus, symptoms can regress 
while the lesion actually expands. After days to weeks, neurological deficits reflect the 
size and location of the structural lesion more closely. Recovery of function from this 
time point is best explained by plasticity and tissue reorganization 
Accordingly, the spontaneous 
which by reorganizing the undamaged neuronal circuits undertake
the circuits damaged by stroke
primarily engage ipsilateral brain regions, although if the damage is severe, contralateral 
brain areas are also recruited 
 
 
Figure 3.1.2 Regression of the functional neurological deficit while the structural lesion 
grows.  
Early in the course of stroke, clinical symptoms mostly reflect an impairment of function (
but not necessarily a structural lesion (
because of therapy, recover function, which explains why symptoms in patients can regress
structural lesion actually grows (adapted from 
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(Wieloch and Nikolich, 2006
an be restored within the penumbra 
, the structural lesion consolidates over time and might 
(Dirnagl et al., 1999
functional recovery has been attributed to brain plasticity 
s the functionality of 
. Recovery processes, both in humans and animal models
(Biernaskie et al., 2005, Kim et al., 2005, 
dark grey). Over time, some areas either spontaneously, or
(Dirnagl et al., 1999)). 
 the 
-
). Initially, the 
). 
, 
Ward, 2005).  
 
light grey) 
 
 while the 
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Stroke and brain plasticity 
The term plasticity was introduced in neurosciences by an Italian psychiatrist Ernesto 
Lugano in 1906 (Berlucchi, 2002), however the important studies in this field were 
initiated by Donald Hebb. More than half a century ago, he postulated that neuronal 
cortical connections are strengthened and can be remodeled by our experience (Hebb, 
1947). Since then, many studies have demonstrated chemical and anatomical plasticity 
in the cerebral cortex of adult animals (Bennett et al., 1964, Rosenzweig, 1966). Another 
aspect of brain plasticity, first and most extensively demonstrated by Merzenich and 
coworkers, was that cortical representation areas and cortical maps can be modified by 
sensory input, experience, and learning, as well as in response to brain lesions 
(Merzenich et al., 1983, Merzenich et al., 1984, Jenkins and Merzenich, 1987, Xerri et al., 
1998). Thus, the potential relevance of those data for stroke rehabilitation was proposed 
more than a decade ago (Jenkins and Merzenich, 1987). Furthermore, synaptic plasticity 
and dendritic spines number in cortical horizontal connections has been proposed to 
underlie cortical map reorganization (Hess and Donoghue, 1994, Buonomano and 
Merzenich, 1998). At the structural level, neuronal plasticity can be defined in terms of 
dendritic and axonal arborization, number of neurons, spine density, synapse number 
and size, and receptor density (Pekna et al., 2012). These structural components of 
neuronal plasticity jointly determine the complexity of neuronal networks and their 
activity, and contribute to functional recovery after stroke and other central nervous 
system injuries (Pekna et al., 2012). Numerous mechanisms are likely to be involved in 
brain plasticity. Modifications of synaptic connection and reorganization of adult cortical 
areas are thought to involve long-term potentiation (LTP) and long-term depression 
(LTD). LTP leads to an increased postsynaptic response and therefore increases synaptic 
strength, whereas LTD is characterised by a reduction in synaptic strength. Both LTP 
and LTD are important mechanisms by which information is thought to be stored in the 
mammalian central nervous system (Bear and Malenka, 1994, Feldman et al., 1999). 
However, despite 30 years of research in this area the detailed mechanisms remain not 
fully understood. Brain plasticity occurs at many levels, from molecules to cortical 
reorganization, therefore strategies promoting synapse and network level plasticity 
leading to the recovery of function, appear to be very promising.  
The stroke outcome may be influenced by several factors: the time after injury, 
lesion site and the integrity of cortical and subcortical connections. Thus, the location 
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and sequence of post-stroke mechanisms are crucial in the recovery process and can 
offer different types of treatment opportunities. The recovery of neurological function in 
patients who have suffered a stroke can be mimicked in experimental animal models, in 
which a repertoire of overlapping recovery-promoting processes have been identified 
(Fig. 3.1.3). After stroke, the central nervous system (CNS) rearranges its neural 
networks to rapidly reorganize structure and function. Recovery process involves 
distinct phases, i.e. activation of cell repair, functional cell plasticity (changing the 
properties of existing neuronal pathways) and neuroanatomical plasticity leading to the 
formation of new connections. After the initial events during the first days of recovery, 
the synapses of surviving neurons in addition to silent synapses and pathways of areas 
remote from the infarct, are activated. Early during recovery, new glial cells and 
neuroblasts are generated and migrate into peri-infarct areas or contralateral remote 
regions. During the following 2–3 weeks, neuroanatomical plasticity (axonal sprouting, 
dendritic and spine growth) is enhanced by the milieu created by surviving neurons and 
proliferating parenchymal cells. In addition, angiogenesis is stimulated, and contributes 
to the formation of new vessels in the peri-infarct areas. Finally, once novel neural 
networks are established, they are stabilized by an experience driven learning process 
(Wieloch and Nikolich, 2006). Because the spontaneous recovery is usually limited and 
therefore insufficient, the strategy of restorative therapies is to promote the endogenous 
brain restorative events in order to boost brain remodeling and reorganization (Nudo et 
al., 1996, Traversa et al., 1997). These targeted endogenous processes underlying brain 
plasticity include stroke-induced change in expression of neuroplasticity-related 
markers (Carmichael et al., 2005), neurogenesis (Zhang et al., 2001a, Hou et al., 2008), 
synaptogenesis (Stroemer et al., 1998), angiogenesis (Chen et al., 2003), axonal 
sprouting (Papadopoulos et al., 2002, Wiessner et al., 2003), inhibition of astrogliosis (Li 
et al., 2005b), anti-inflammation (Bacigaluppi et al., 2009). Indeed, during the recent 
years this concept has received support in a number of animal studies showing that 
application of pharmacological agents and various types of cells (including stem cells 
and neuronal precursors) can improve functional recovery after stroke (Shyu et al., 
2004, Chopp et al., 2009, Zhang and Chopp, 2013). Yet, the success of any given 
therapeutic intervention depends on how well it interacts with the new, stroke-induced 
functional network. At present, only few restorative therapies could be translated into 
clinical trials. Thus, methods inducing or boosting neuronal plasticity in the affected 
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brain combined with currently available acute treatments may represent a new effective 
therapeutic strategy for stroke therapy. The hope is that by understanding mechanisms 
which lead to functional recovery we could enhance the naturally occurring recovery 
capabilities of the brain. 
 
 
 
Figure 3.1.3  An overview of the activated parallel processes and therapeutic approaches 
following stroke.  
The temporal sequence of events is shown along a semi-logarithmic schematic timeline of 180 days 
after injury. Darker shading highlights the maximum intensity of the specific mechanism. Processes 
that are detrimental towards recovery are shown in pink. Processes of cell genesis are shown in 
brown, whereas those that underlie adaptive plasticity are shown in green. Prospective therapies 
that focus on neuroprotection and enhancement of regeneration and functional recovery are shown 
in gray (redrawn from (Wieloch and Nikolich, 2006)). 
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3.2 Sleep  
 
Physiology of sleep 
Sleep, a phylogenetically, highly preserved process identified in all the species studied so 
far, is particularly well developed in the human brain (Cirelli and Tononi, 2008). It is a 
natural, periodically recurring state of inactivity, characterised by the loss of 
consciousness, immobility, typical sleeping posture and reduced responsiveness to the 
external stimuli. In contrast to humans exhibiting a single sleep period of approximately 
8 hours during the dark phase, rodents have a polyphasic sleep pattern with sleep 
episodes throughout the 24 hours, dominating during the light period (Tobler, 1995). In 
addition to sleep-specific behaviour, a reliable definition of vigilance states can be 
obtained by measuring characteristic changes in the brain electrical activity by 
electroencephalogram (EEG) and in muscle tone by electromyogram (EMG). 
Based on the EEG and EMG, the same three vigilance states can be discriminated 
in humans and rodents: wakefulness, non-rapid eye movement (NREM) sleep or slow 
wave sleep (SWS) and paradoxical or rapid eye movement (REM) sleep (Fig. 3.2.1). 
Exclusively in humans, NREM sleep is further subdivided into stages 1 to 3. Wakefulness 
is characterised by the presence of low-amplitude, fast-frequency, irregular EEG pattern 
(beta: 14-30 Hz and gamma: 30-50 Hz frequency ranges), combined with a prominent 
muscle activity in the EMG. During NREM sleep the frequency of EEG activity decreases 
and the amplitude increases, concomitantly with decrease in the muscle tone. The main 
characteristic of NREM sleep is the appearance of slow wave activity (SWA; 0.5-4 Hz). 
REM sleep is characterised by low-amplitude, desynchronized EEG activity and complete 
loss of muscle tone (i.e. atonia). In rodents, the EEG is typically dominated by 
frequencies in the theta band (4-8 Hz) during REM sleep and phasic activity appears as 
twitching of the vibrissae as well as eye movements. Sleep stages alternate in the course 
of the night in a regular manner. The duration of the sleep cycle as well as the 
percentage of NREM and REM sleep during 24 h varies among species (Zepelin et al., 
2005). 
 
 
 
 
 
  
Figure 3.2.1 Electroencephalogram
vigilance states: wakefulness, NREM sleep and REM sleep
 
Sleep is regulated by three distinct mechanisms: a homeostatic, a circadian and 
an ultradian process. The ultradian process is represented by the alterations of NREM
and REM sleep within the sleep cycle. Sleep homeostasis is represented by “process S”, 
which increases during waking and declines during sleep. The circadian process 
(“process C”), on the contrary, is independent of the prior sleep
maintains an approximate 24 h rhythm 
to fall asleep, as well as the 
interaction of processes S and C, 
regulation (Borbely, 1982). 
more intensely and the longer they sleep, as measured in 
amplitude of slow waves, higher arousal threshold, and/or fewer awakenings.
 
Sleep-related mechanisms of neuroplasticity
Although the core function of sleep is still under debate, an increasing body of evidence 
has suggested that sleep plays an important role in neuronal plasticity at different levels 
of brain organization (Huber et al., 2004
2009, Bushey et al., 2011). Experimental data, as well as personal 
that sleep after learning facilitates cogn
and nondeclarative tasks (Gais et al., 2000
2004, Stickgold, 2005). On the othe
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 (EEG) and electromyogram (EMG) traces showing three 
, in rodents. 
-wake history and 
through an intrinsic pacemaker. 
structure and sleep propensity, are determined
as described in “The Two-Process Model” of sleep 
The model explains that the longer animals stay awake, the 
increased number and 
 
, Vyazovskiy et al., 2008a, 
experiences, endorses 
ition and memory consolidation 
, Gais and Born, 2004, Walker and Stickgold, 
r hand, sleep deprivation (SD) impairs new learning 
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Vassalli and Dijk, 
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(Yoo et al., 2007) and compromises induction and/or maintenance of LTP (Davis et al., 
2003, McDermott et al., 2003). Furthermore, it has been shown that expression of genes 
and proteins involved in plasticity processes is differentially regulated during sleep, 
wakefulness and following SD (Cirelli et al., 2004, Vyazovskiy et al., 2008a). Numerous 
genes responsible for the biosynthesis of macromolecules, especially those involved in 
the memebrane/myelin structure and in lipid metabolism, have been reported to be 
upregulated during sleep (Cirelli et al., 2004, Mackiewicz et al., 2007). This sleep-
dependent regulation of gene expression is particularly relevant during the recovery 
from brain injury, as axonal sprouting is an important component of restorative 
processes. It has been also proposed that sleep may promote endogenous neurogenesis 
in the adult brain. Rodents subjected to SD or sleep restriction were shown to have a 
reduction in the rate of cell proliferation and in the number of newborn cells containing 
matured neuronal marker (Guzman-Marin et al., 2005, Hairston et al., 2005, Guzman-
Marin et al., 2007, Meerlo et al., 2009). Functionally, the SD-induced suppression of 
neurogenesis has been related to the impaired learning performance after sleep 
disruption (Hairston et al., 2005).  
Recently, a great amount of sleep research has been focused on a theory 
proposing that sleep is essential for synaptic homeostasis, that is the recalibration of the 
net synaptic weight (strength and number) to an energetically sustainable level (Cirelli 
et al., 2004). The proposed hypothesis, known also as the “Synaptic Homeostasis 
Hypothesis” (Tononi and Cirelli, 2003, 2006), assumes that uptake of information and 
activity during wakefulness is associated with synaptic potentiation, i.e. an upscaling of 
synaptic strength, while sleep, in particular NREM sleep, is associated with a global 
downscaling of synaptic strength. The maintenance of synapses is expensive in terms of 
space, energy and cellular supplies. Therefore, the synaptic downscaling during sleep is 
crucial to counter synaptic potentiation brought up by waking through removing weak 
synapses, and thereby increasing the signal-to-noise ratio in neural circuits. Otherwise 
the available resources of energy and space would be exceeded, which in turn could lead 
to an unrestrained synaptic weight growth and saturation of ability to learn (Vassalli 
and Dijk, 2009). This further supports the importance of sleep, which by providing 
optimal conditions for unbiased offline processing, is needed for renewal of brain energy 
stores.  
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SWA is a well established marker of sleep intensity, which increases as a function 
of prior wakefulness and declines during sleep (Borbely, 1982), as mentioned above. In 
the model of synaptic homeostasis theory, SWA high at the sleep onset reflects the 
increased overall strength of connections in the synaptic network acquired during 
waking period. But at the same time, slow waves represent a mechanism for 
downscaling which results in its gradual decrease of activity across sleep (Tononi and 
Cirelli, 2003, 2006). This hypothesis is supported by many studies pointing to close 
relationship between slow waves during NREM sleep and synaptic plasticity processes. 
Experimental data showed that molecular (GluR1-containing AMPA receptor [AMPAR]) 
and electrophysiological markers of synaptic potentiation increased after a periods of 
waking and decreased after recovery sleep, whereas markers of synaptic depression 
were found to be elevated after sleep (Lubenov and Siapas, 2008, Vyazovskiy et al., 
2008a). Moreover, neuronal firing rate was increased after sustained wakefulness and 
decreased after sustained sleep (Vyazovskiy et al., 2009). Furthermore, several reports 
provided evidence for a close association between synaptic potentiation related to 
wakefulness and an increase in SWA during subsequent sleep. Both in humans and 
animals the brain regions that have been stimulated by intense activities during waking 
showed higher SWA in subsequent NREM sleep (Kattler et al., 1994, Huber et al., 2004, 
Hanlon et al., 2009), while areas that have been less engaged showed reduced SWA 
(Huber et al., 2006). In addition, those specific waking activities triggered induction of 
plasticity-related genes in the cortex and this was correlated to the extent of SWA 
response during the subsequent sleep episode. Observed local increase of SWA was 
positively correlated with the improvement in performance on the next morning (Huber 
et al., 2004, Huber et al., 2007, Hanlon et al., 2009).  
Synaptic homeostasis concept stimulated a unique surge of research targeting the 
role of sleep in brain plasticity. Recently published studies challenged the theory that 
NREM sleep is alone responsible for establishing synaptic homeostasis. Accordingly, 
Cheauvette et al. (Chauvette et al., 2012) showed that during NREM sleep, the brain 
responsiveness was rather upscaled than downscaled, as measured by evoked 
potentials, while Grosmark et al. (Grosmark et al., 2012) found that downscaling in 
hippocampal networks might be mediated through REM sleep rather than SWS. 
Together, these studies speculated that NREM sleep, through slow waves, supports 
synaptic upscaling, while subsequent REM sleep, through theta activity, supports 
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downscaling. This implies that processes occurring during REM sleep should be taken 
into consideration while talking about synaptic plasticity. Beyond this, recent data 
suggests that the key mechanism launching the consolidation of newly acquired 
memories is the ripple-associated replay during SWS (Diekelmann and Born, 2010). It 
has been speculated that the interactions between ripples, i.e. high-frequency 
hippocampal oscillations (100-300 Hz) and slow oscillations may be crucial for synaptic 
consolidation. Therefore, it is clear that a number of details in connection with synaptic 
homeostasis should be still clarified.  
Taken together, interaction between changes in sleep EEG and the plasticity-
related markers at the molecular, cellular and network levels provide a link between 
sleep and brain plasticity. 
 
 
3.3 The role of sleep in stroke recovery 
 
The role of sleep in stroke patients 
Sleep-wake disturbances are frequent after stroke and appear to have a detrimental 
impact on rehabilitation and long-term neurological outcome (Bassetti and Hermann, 
2011). Sleep-wake disturbances observed in stroke patients include insomnia, sleep 
fragmentation, excessive daytime sleepiness (EDS) and, even if less frequently, 
hypersomnia (Hermann and Bassetti, 2009). Although there is no distinct relation to the 
infarct topography and size, it appears that hypersomnia and EDS are often associated 
with severe hemispheric stroke and damage in the paramedian thalamus, wheareas 
insomnia is increased with mild superficial hemispherical infarction (Autret et al., 2001, 
Muller et al., 2002, Vock et al., 2002, Hermann et al., 2008, Siccoli et al., 2008). Clinical 
outcome studies indicate that stroke patients with sleep-wake disturbances suffer more 
frequently from neuropsychiatric (depression and anxiety) and cognitive (memory and 
attention) disorders, dementia, and physical impairments (Leppavuori et al., 2002, 
Hermann and Bassetti, 2009). Recently, Sicolli et al. (Siccoli et al., 2008) have reported a 
positive correlation between the amount of sleep and cognitive functions during both 
the acute and the recovery phases after stroke.   
Although the role of sleep in the recovery process after brain injuries remains 
unclear, clinical observations together with few findings in basic research suggest that 
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sleep may be a key modulator of stroke recovery. Accordingly, if poor functional 
outcome after stroke is linked to sleep-wake disturbances and sleep is instead believed 
to be important for the endogenous neuronal remodeling process (Huber et al., 2004, 
Huber et al., 2007, Hanlon et al., 2009), strategies aiming to improve and promote sleep 
hold a great promise for benefiting the long-term functional outcome after stroke. 
However, until now only few studies have investigated the relationship between these 
two processes and the impact of sleep on stroke pathophysiology and recovery-related 
brain repairing mechanisms.  
 
Effects of sleep modulation in animal models of stroke 
Experiments using animal stroke models showed that SD performed prior to global or 
focal cerebral ischemia attenuated stroke severity, inflammatory response and cell 
death in mice and rats (Moldovan et al., 2010, Cam et al., 2013). Furthermore, Gao et al. 
have recently carried out several studies, in which sleep has been altered either by sleep 
deprivation or by clinical relevant sleep-promoting drug. The main common finding of 
these experiments was that manipulation of sleep after focal ischemia affected stroke 
outcome. Thus, SD and sleep disturbances (SDis) performed shortly after stroke resulted 
in an aggravation of the infarct size and increase in the number of damaged cells (Gao et 
al., 2010). In a further study investigating the long-term outcome after stroke, disruption 
of sleep impeded functional recovery, as assessed by the single pellet reaching (SPR) test 
during a 5-week period (Fig. 3.3.1). This effect was accompanied by the impairment of 
the brain repairing system, such as suppressed axonal sprouting, synaptogenesis (Fig. 
3.3.2A), and neurogenesis (Fig. 3.3.2B) (Zunzunegui et al., 2011). The effect of sleep 
disruption on expression of neuroplasticity-related genes has been also tested by 
probing a small set of genes that may influence axonal sprouting, such as promoting 
(GAP43 and c-jun), and inhibiting (neurocan, ephrin A5 and ephrin B1) genes 
(Carmichael, 2005). The data showed that SDis induced a substantial increase in 
expression of the axonal growth-inhibiting gene neurocan (Gao et al., 2010), providing 
evidence for sleep modulation of stroke at the molecular level. On the other hand, 
administration of gamma-hydroxybutyric acid (GHB), considered as a sleep-promoting 
drug, immediately after reperfusion accelerated motor function recovery in mice (Gao et 
al., 2008). However, whether these GHB-induced changes on stroke outcome were sleep-
dependent has not been analysed.  
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Overall, these results suggest that the sleep effects on stroke can be partially 
similar to those occurring in the healthy brain, including the altered expression of 
plasticity-related genes. However, the underlying mechanisms have not been elucidated 
yet. Ischemic stroke, due to a sudden reduction of blood flow, triggers a cascade of 
events, i.e. energy failure, excitotoxicity, free radical generation and inflammation, which 
consequently leads to necrosis and apoptosis (Dirnagl et al., 1999). In healthy brain, 
sleep disruption has been reported to increase the expression of excitatory 
neurotransmitter receptors (Vyazovskiy et al., 2008b), to decrease the antioxidative 
stress parameters (D'Almeida et al., 1998, Singh et al., 2008), and to elevate the 
production of certain proinflammatory cytokines, such as IL-1β, IL-6, IL-17 and TNFα 
(Shearer et al., 2001, Vgontzas et al., 2004, van Leeuwen et al., 2009). These sleep loss-
triggered changes could likely be implicated in the stroke pathophysiology via 
exacerbating ischemic cascade events.  
 
 
Figure 3.3.1 SDis-induced impairment in stroke recovery, evaluated by the single pellet 
reaching task.  
A. Photographs of a rat reaching (arrows) a pellet located in an indentation on the shelf, through a 
slot opened in the front of a training box B. Reaching success is presented as percentage of the 
baseline (BL) *P<0.05,**P<0.01 (redrawn from (Zunzunegui et al., 2011)). 
  
22 
 
Figure 3.3.2 SDis-induced reduction in axonal sprouting, synaptogenesis and cell 
proliferation.                     
A. Effects of SDis on axonal sprouting of corticostriatal and corticocortical projection neurons in the 
contralateral hemisphere. Upper panel: quantification of BDA labeled corticostriatal (left panel) and 
intercortical (right panel) axons. Lower panel: expression of synaptophysin mRNA. *P<0.05, 
**P<0.01. B. Numerous newborn cells labeled with BrdU in the peri-infarct area, visualized by single 
immunofluorescence staining. Scale bar, 50 μm. n = 4 per group. **P<0.01 (redrawn from 
(Zunzunegui et al., 2011)). 
 
 
Taken together, all of the mentioned experiments provide strong evidence that 
sleep might play a dual role in brain repair, promoting neuroprotection in the acute 
phase and/or enhancing neuroplasticity in the delayed phase after stroke. Therefore, it 
has been and still is of high interest to perform further experiments exploring the 
potential of sleep promotion for improving stroke outcome.  
 
 
 
 
 
 
 
 
A B 
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3.4 Sleep-promoting agents: baclofen and gamma-hydroxybutyrate 
 
One of the most accessible methods to influence sleep is to use pharmacological 
approach. The administration of specific drugs inducing changes in sleep architecture 
and/or sleep intensity offer a promising tool to manipulate stroke outcome. Since 
gamma-aminobutyric acid (GABA) have been shown to play a major role in sleep 
regulation (Gottesmann, 2002), substances affecting GABAergic transmission may thus 
be used as an effective way to manipulate sleep.  
Metabotropic receptors are the site of action for the majority of therapeutic 
agents used currently in clinical practice. Nevertheless, there are many receptors in this 
class that have not been yet therapeutically exploited, including GABAB receptors. The 
natural ligand for GABAB receptor is GABA, which is well established as the principal 
inhibitory neurotransmitter. The GABAB receptors are located in the brain both pre- and 
post-synaptically where they are coupled to Ca2+ and K+ channels. Operating through 
second messengers, they cause increased outward K+ or decreased Ca2+ conductance 
(Bowery, 2006). In consequence, their activation leads to various effects resultant from 
inhibition of the transmitter release and/or neuronal hyperpolarization. Hence, 
stimulation of these receptors can produce numerous outcomes that might be amenable 
to drug development. Additionally, GABA has been shown to be critical for cortical 
plasticity and sensory mapping. Altering GABAergic transmission modifies sensory maps 
during development (Hensch, 2005), and produces rapid alterations in adult cortical 
maps that resemble changes occurring after stroke (Foeller et al., 2005). Thus, 
GABAergic mechanisms may mediate changes in neuronal excitability that have a central 
role in functional recovery of the peri-infarct cortex after stroke. 
Baclofen (Bac) is a structural analog of GABA mediating its effects directly via 
activation of the GABAB receptors. Historically, Bac was originally developed in the 
1920s to treat epilepsy as a derivative of diazepam. Although its clinical effect on 
epilepsy appeared to be disappointing, it was found to be beneficial on diminishing the 
number and severity of muscle spasms. It has been therefore used in the United States 
since 1977 for treatment of spasticity in several disorders such as multiple sclerosis or 
cerebral palsy (Albright et al., 1991, Paisley et al., 2002, Bensmail et al., 2006). 
Gamma-hydroxybutyric acid (GHB) is a naturally occurring compound in the 
mammalian brain that is both, a precursor and a degradation product of GABA. It is 
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found in micromolar concentrations (1–4 mM) in all regions of the mammalian brain 
and considered to act as a neuromodulator or neurotransmitter (Cash, 1994, Maitre, 
1997). GHB binds with high affinity to its own GHB receptor, which was found to have 
the highest density in the hippocampus, cortex and the thalamus (Hechler et al., 1992, 
Castelli et al., 2000). However, accumulating evidence suggests that most of the 
pharmacological and clinical effects of exogenously administered GHB, including 
sedation, anaesthesia and sleep are mediated by activation of GABAB receptors (Carai et 
al., 2001, Kaupmann et al., 2003, Carai et al., 2008, Vienne et al., 2010). Therefore, it has 
been widely used in the clinical practice as an anaesthetic adjuvant (Kleinschmidt et al., 
1999) and as a treatment for various sleep disorders, particularly narcolepsy with 
cataplexy (Scrima et al., 1989, Lammers et al., 1993, Fuller and Hornfeldt, 2003, 
Poryazova et al., 2011). Although GHB has been proposed as a biologically active 
neuromodulator (Maitre, 1997), the precise function of endogenous GHB in the brain is 
unknown. 
Given that both, Bac and GHB act as GABAB receptor agonists, they share some 
commonality of action. For example, they have both found clinical use in the treatment 
of alcohol and opiate withdrawal and in promoting long-term abstinence from these 
drugs’ action (Cousins et al., 2002). Importantly, both drugs differ in the binding affinity, 
i.e. GHB is a low-, while Bac is a high-affinity agonist of GABAB receptors (Lingenhoehl et 
al., 1999). Hence, there are some notable differences in the effects mediated by both 
drugs. Unlike GHB, Bac has been shown to have few euphoric effects, reduced abuse 
potential and no physical dependence (Kaupmann et al., 2003, Carter et al., 2009). 
Additionally, Bac is not used in anaesthesia and has been never reported to be effective 
in treatment of narcolepsy (Kaupmann et al., 2003). However, the functional correlates 
and cellular mechanisms contributing to these differential responses remain elusive. 
The effects of Bac and GHB on stroke outcome in animals are controversial. 
Moreover, the effects of both substances have been evaluated only when the drug was 
administered during or before the acute phase of ischemic injury. It had been shown that 
Bac injections before or immediately after stroke had no beneficial effect on mortality, 
cellular damage and memory (Rosenbaum et al., 1990), whereas it was neuroprotective 
at the high dose when administered 30 min before (Zhang et al., 2007) or 5 min after 
(Jackson-Friedman et al., 1997) ischemia. Several laboratories have shown the 
neuroprotective effect of GHB (Vergoni et al., 2000, Ottani et al., 2003, Ottani et al., 
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2004) after stroke.  As mentioned already in section 3.3, recent study in mice showed 
that GHB administrated shortly after ischemia, accelerated functional recovery without 
significantly changing stroke morphology (Gao et al., 2008). However, the mechanisms 
underlying this GHB-induced beneficial effects on stroke outcome remain unclear.  
Both, Bac and GHB have been shown to affect sleep. Administration of Bac and 
GHB has been demonstrated to increase NREM sleep duration and intensity in humans 
(Lapierre et al., 1990, Series et al., 1992, Van Cauter et al., 1997, Darbari et al., 2005, 
Huang and Guilleminault, 2009, Vienne et al., 2012) and to induce slow- wave sleep 
(SWS) in rats (Godschalk et al., 1977, Monti et al., 1979, Manfridi et al., 2001, Ulloor et 
al., 2004, Darbari et al., 2005, Datta, 2007, Huang and Guilleminault, 2009). Interestingly, 
both drugs have been also reported by recent studies to induce sub-anaesthetic state 
different from physiological sleep (Meerlo et al., 2004, Vienne et al., 2010). Taken 
together, some findings suggested physiological sleep-promoting effects and 
involvement in homeostatic sleep regulation of both drugs, while others contradicted 
them. Therefore, the effects of Bac and GHB on sleep and thus possible endorsement of 
recovery after ischemic insult remain still unclear. 
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3.5 Thesis aims 
 
The overall goal of the current thesis was to investigate how alterations in sleep after 
ischemic stroke affect recovery processes in rats. Based on the previous studies 
providing a major insights about a possible beneficial role of sleep in brain repair (Gao 
et al., 2008, Gao et al., 2010, Zunzunegui et al., 2011, Cam et al., 2013), we hypothesized 
that promotion of sleep, and in particular of slow wave activity, could enhance 
endogenous mechanisms of neuronal plasticity, which would improve functional 
recovery. Sleep could serve not only as a clinically relevant new approach to facilitate 
neurological recovery after brain damages but also as a useful tool to examine plasticity 
under pathophysiological conditions such as stroke. Therefore, it is of high interest to 
further explore this unique, poorly understood research area and unveil the importance 
of sleep in brain restoration.  
 
In order to examine our hypothesis, specific aims were addressed in two main 
experiments. 
 
1. The aim of the first project (Manuscript 1) was to characterise the changes induced 
by Bac and GHB in sleep, EEG activity and behaviour in healthy rats. The main focus of 
this work was to explore whether each of the drug had sleep-promoting properties and 
therefore, possible therapeutic potential. Although several studies have investigated the 
effects of Bac and GHB on sleep in healthy humans and animals, their effects remain still 
unclear. In order to elucidate if the time of the day affected the action of the drugs, Bac 
and GHB were given at two different time points (beginning of the light and of the dark 
phase), corresponding to physiological circadian periods of rest and activity in rats.  
 
2. The aim of the second project (Manuscript 2) was to evaluate the effects of sleep 
promotion with Bac on motor function recovery and endogenous mechanisms involved 
in neuronal plasticity (axonal sprouting and neurogenesis) after ischemic stroke. The 
choice of Bac was based on the data obtained in the first study. In order to investigate 
the drug effects on brain repairing processes, the targets of neurorestorative therapies, 
Bac was administered twice a day starting 24 h after ischemic injury for a period of 10 
days. This delayed approach is of clinical significance since it falls out of the time 
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window available for acute neuroprotective treatments, which is within 6 h after 
ischemia onset. Furthermore, the plastic events that characterise the semi-acute phase 
after stroke diminish and slow with time. Therefore, an important challenge is to find 
ways to widen the therapeutic window and to keep it open for a longer period of time in 
order to optimise post-stroke recovery.  
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ABSTRACT 
Study objectives: Animal and human studies have shown that sleep may have an impact 
on functional recovery after brain damage. Baclofen (Bac) and gamma-hydroxybutyrate 
(GHB) were shown to induce physiological sleep in humans, however, their effects in 
rodents are unclear. The aim of this study is to characterise sleep and EEG after Bac and 
GHB administration in rats.  
Design: Rats were implanted with EEG/EMG electrodes for sleep recordings. GHB, Bac 
or saline were injected 1h after light and dark onset. Vigilance states and EEG spectra 
were quantified. 
Settings: Basic sleep research laboratory. 
Measurements and Results: Bac and GHB induced a non-physiological state 
characterised by atypical behaviour and abnormal EEG pattern. After termination of this 
state Bac was found to increase the duration of NREM and REM sleep, reduce sleep 
fragmentation and affect NREM sleep episode frequency and duration (p<0.05). GHB had 
no major effect on vigilance states. Bac increased EEG power density in NREM sleep in 
the frequencies 1.5-6.5 and 9.5-21.5 Hz compared to saline (p<0.05), while GHB 
enhanced power in 1-5 Hz and reduced in 7-9 Hz frequency band. SWA in NREM sleep 
was enhanced during first 1-2 h following termination of the non-physiological state. 
The magnitude of the drug effects was stronger during the dark phase. 
Conclusion: In contrast to GHB, Bac facilitated and consolidated sleep and promoted 
EEG delta oscillations after the end of the drug effect. The effects of sleep promotion on 
functional recovery after stroke could be tested with baclofen in both humans and rats.  
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INTRODUCTION 
Promoting sleep has been proposed as a promising new approach to facilitate functional 
recovery after brain damage (Carmichael and Chesselet, 2002, Gao et al., 2008, Bassetti 
and Hermann, 2011, Cam et al., 2013). Baclofen (Bac) and gamma-hydroxybutyrate 
(GHB) have been suggested to induce physiological sleep in humans, however, their 
effects in rodents are unclear.  
Gamma-hydroxybutyric acid, an endogenous metabolite of gamma-aminobutyric 
acid (GABA), is found in all regions of the mammalian brain and considered to act as a 
neuromodulator or neurotransmitter (Cash, 1994, Maitre, 1997). High doses of 
exogenous GHB induce sedation, anaesthesia and sleep (Cash, 1994, Carai et al., 2001). 
Therefore, it has been widely used in the clinical practice as an anaesthetic adjuvant 
(Kleinschmidt et al., 1999) and as treatment for narcolepsy with cataplexy (Scrima et al., 
1989, Lammers et al., 1993, Fuller and Hornfeldt, 2003, Poryazova et al., 2011). 
Although most of the pharmacological and clinical effects of exogenously administered 
GHB are mediated by GABAB receptors (Carai et al., 2001, Kaupmann et al., 2003, Carai 
et al., 2008, Vienne et al., 2010), GHB has its own endogenous receptors (Hechler et al., 
1992, Castelli et al., 2000) with distinct distribution in the brain (Maitre, 1997, van 
Nieuwenhuijzen et al., 2009). Yet, the precise function of endogenous GHB remains 
unknown.  
Baclofen is another GABAB receptor agonist, usually used to treat spasticity 
(Albright et al., 1991, Paisley et al., 2002, Bensmail et al., 2006). Although both drugs 
bind to GABAB receptors, GHB has a lower affinity than Bac (Lingenhoehl et al., 1999, Wu 
et al., 2004). It has been shown that GHB and Bac induce c-Fos expression in distinct 
brain regions (van Nieuwenhuijzen et al., 2009). Interestingly, only GHB administration 
activated brain areas involved in the regulation of sleep and reward processes. 
Behavioural effects of GHB and Bac are different. In contrast to GHB, Bac has reduced 
abuse potential, euphoric effects and does not lead to physical dependence (Kaupmann 
et al., 2003, Carter et al., 2009). Thus, it is not used in anaesthesia or in treatment of 
narcolepsy (Kaupmann et al., 2003).  
Several studies have explored the effects of GHB and Bac on sleep in healthy 
humans and animals. It has been shown that GHB decreases sleep latency and increases 
deep slow-wave sleep (SWS) in humans (Lapierre et al., 1990, Series et al., 1992, Van 
Cauter et al., 1997, Vienne et al., 2012) and enhances SWS in rats (Godschalk et al., 1977, 
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Monti et al., 1979). Interestingly, GHB has been also reported to induce 
hypersynchronous electroencephalogram (EEG) activity in awake humans (Mamelak et 
al., 1977, Van Cauter et al., 1997) and animals (Godschalk et al., 1977, Stock et al., 1978, 
Meerlo et al., 2004). Bac increased non-rapid eye movement (NREM) sleep and 
promoted EEG delta waves during NREM sleep in humans (Darbari et al., 2005, Huang 
and Guilleminault, 2009, Vienne et al., 2012) and SWS in rats (Manfridi et al., 2001, 
Ulloor et al., 2004, Darbari et al., 2005, Datta, 2007, Huang and Guilleminault, 2009). The 
effects of Bac on rapid eye movement (REM) sleep remain controversial. Infusion of Bac 
into the pedunculopontine tegmental nucleus suppressed REM sleep in rats (Ulloor et 
al., 2004, Datta, 2007), whereas unilateral Bac infusion into the nucleus basalis of 
Meynert had no effect on REM sleep (Manfridi et al., 2001). Recent studies in mice have 
demonstrated that both drugs induce sub-anaesthetic state different from physiological 
sleep (Meerlo et al., 2004, Vienne et al., 2010). Altogether, it is still unclear whether Bac 
and GHB induce physiological sleep in rodents.  
The aim of the present study was to investigate the effect of Bac and GHB on 
behaviour, vigilance states and EEG pattern in rats, to evaluate their sleep-promoting 
properties and possible therapeutic potential. To address a circadian influence on the 
magnitude of the effects, the drugs were injected at the onset of the light and dark phase, 
which corresponds to periods of rest and activity in the rats.   
 
 
METHODS 
Animals 
Adult male Sprague-Dawley rats (n = 23; Harlan Laboratories, Netherlands), weighing 
250-270 g at the beginning of the experiment, were maintained on a 12 h light-dark 
cycle (light onset at 08:00 or 09:00) and 22 ± 0.5°C ambient temperature. They were 
kept individually in Macrolon cages and provided with food and water ad libitum. The 
experiments were carried out with governmental approval according to local guidelines 
for the care and use of laboratory animals in the University Hospital Zürich, Switzerland 
(where A.H., S.P., B.G. and C.B. worked, when the experiments were conducted). 
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Surgery  
All rats were implanted epidurally with EEG and electromyogram (EMG) electrodes 
under deep anaesthesia (2% isoflurane in 30% O2 and 70% N2O). Four gold-plated mini-
screws were positioned in the skull over the motor cortex of the right and left 
hemispheres (+/-2 mm to bregma, 2 mm lateral to midline). Electrodes were connected 
to stainless steel wires and fixed to the skull with dental cement. Two gold wires were 
inserted bilaterally in the neck muscles for EMG recording. At least 8-10 days were 
allotted for recovery from surgery before the experiment. 
 
Drugs 
GHB (Xyrem® - Sodium Oxybate, donated by UCB-Pharma) and Bac (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland) were diluted in saline (0.9% NaCl) to obtain 100 
mg/ml GHB and 3 mg/ml Bac stock solutions. Bac (10 mg/kg) and two doses of GHB 
(150 or 300 mg/kg) were administered intraperitoneally (i.p.). The doses were chosen 
based on the previous studies (Meerlo et al., 2004, Koek et al., 2005, Vienne et al., 2010).  
 
Experimental protocol  
Rats were subdivided into four treatment groups, including Bac-10 (n = 6), GHB-150 (n 
= 6), GHB-300 (n = 5), and saline (n = 6; Fig. 4.1.1). Drugs were injected 1 h after light 
and dark onset. Each rat received two injections (one during the light phase and one 
during the dark phase) 2-3 days apart to allow drug washout. After each injection rats 
were visually observed by the investigator and their behaviour was video recorded. 24-h 
EEG and EMG recordings were performed during baseline and after drug administration.  
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Figure 4.1.1 
EEG and EMG were recorded during a 24-h baseline day and following drug injections performed 1 h 
after light and dark onset. Every rat received two intraperitoneal injections. At least 2-3 days were 
allowed for drug washout between injections. Four treatment groups were designed: Baclofen 10 
mg/kg (Bac-10, n = 6), GHB 150 mg/kg (GHB-150, n = 6), GHB 300 mg/kg (GHB-300, n = 5) and 
saline (n = 6). 12-h light and 12-h dark phase are indicated by white and grey bars, respectively. 
 
EEG recording and analysis 
EEG and EMG were sampled at 200 Hz, signals were amplified, filtered and converted 
into analog-to-digital signals. Hardware EMBLA and Somnologica-3 software (Medcare 
Flaga, Iceland) were used. Activity in the 50 Hz band was discarded from the analysis 
because of power line artifacts. Power spectra of the EEG were obtained by a discrete 
Fourier transformation (range: 0.75–25 Hz; frequency resolution: 0.25-Hz bins; time 
resolution: consecutive 4 sec epochs; window function: hamming). Three vigilance 
states - NREM sleep, REM sleep and wakefulness - were scored visually with 4-sec 
epochs. Standard criteria were used to identify vigilance states (Tobler et al., 1997). 
Epochs were assigned to a specific vigilance state when more than half of the epoch 
fulfilled the criteria for that state. Epochs containing EEG artifacts were excluded from 
spectral analysis in both derivations (14% of recording time, most of them (11%) 
occurred during wakefulness). In addition to conventional vigilance states we 
introduced two new states resembling sleep and wakefulness following administration 
of the drugs (“drug-induced states”). These states were characterised by atypical 
behaviour and abnormal hypersynchronous EEG pattern. The first 4 sec epoch following 
drug administration was taken as the onset of the non-physiological vigilance state and 
the last epoch of abnormal EEG (determined by visual inspection of EEG) was taken as 
the end of the state. Our analysis was focused on the time period following the end of 
this state. 
24-h Baseline
Drug washout
(at least 2-3 days)
Injection Injection
Design of the experiment
Drug Drug
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Three recording periods were scored and evaluated for every animal: 24-h 
baseline, 11 h following injection during the light phase and 11 h following injection 
during the dark phase. 
 
Statistical analysis 
Drug and time of day effects were evaluated by a repeated-measures or mixed-models 
analysis of variance ANOVA (SAS software, SAS Institute, Cary, NC, USA). Post-hoc paired 
and unpaired t-test, Tukey-Kramer, Bonferroni and Kruskal-Wallis tests were performed 
if the results of the ANOVA reached statistical significance (p<0.05). All reported values 
are means ± SEM. 
 
 
RESULTS 
Effects of baclofen on behaviour, vigilance and EEG 
Behaviour and vigilance states. We first studied the effect of Bac administration on 
sleep-wake behaviour. After injection of a single 10 mg/kg dose of Bac (Bac-10), rats 
were lying down immobile, their body posture was unnaturally flat with limbs stretched 
sideways, while the eyes remained open (Fig. 4.1.2A). This behavioural response 
occurred 5-10 min after drug injection and lasted for 40-70 min. Circadian time of the 
drug administration had no effect on behavioural response. Concomitant to this 
behavioural response, we found that Bac-10 induced specific EEG pattern characterised 
by hypersynchronous slow waves (Fig. 4.1.2B), which progressively predominated EEG. 
The “drug-induced” state lasted 246 ± 38 and 216 ± 24 min during the light and dark 
phase, respectively.  
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Figure 4.1.2 Effect of baclofen 10 mg/kg (Bac-10) and GHB 300 mg/kg (GHB-300) on 
behaviour and EEG pattern.  
A. The picture of the rat 30 min after Bac-10 administration: atypical flat body posture with eyes 
open. B. Representative 30 sec raw EEG and EMG traces during physiological NREM sleep and 
following Bac-10 administration in rats. C. Representative 30 sec raw EEG and EMG traces during 
physiological NREM sleep and following GHB-300 administration in rats.  
 
When acute effects of the drug on behaviour and EEG vanished, normal vigilance 
states could again be determined. Therefore, long-term effects of the drug on the total 
amount of wakefulness, NREM sleep, REM sleep and corresponding EEG spectra were 
evaluated after the termination of the non-physiological ”drug-induced” state. We found 
that NREM sleep was increased during the light and dark phase compared to the 
corresponding baseline values (p<0.05, paired t-test; Table) and during the dark phase 
compared to the saline treatment (p<0.005, unpaired t-test; Fig. 4.1.3A). The drug effect 
on NREM sleep was stronger during the dark phase (91.4 ± 8.1 vs. 15.7 ± 6.0 min, 
p<0005, paired t-test; values were computed as a difference between treatment and 
corresponding baseline). The duration and frequency of NREM sleep episodes were 
affected by the timing of Bac administration. Thus, during the light phase Bac-10 
increased the duration of the episodes (p<0.01, paired t-test; Fig. 4.1.3B), but reduced 
their frequency (p<0.05), while during the dark phase it increased the frequency of the 
100 µV
500 µV
5 sec
B.A.
EEG
EMG
EEG
EMG
NREM sleep
NREM sleep
100 µV
500 µV
GHB-300 (30 min post-injection) 
5 sec
EEG
EMG
EEG
EMG
C.
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episodes (p<0.0001) without changing their duration. Moreover, the number of NREM 
sleep and waking episodes (not shown) was significantly different from saline treatment 
in the dark phase (p<0.01, unpaired t-test; Fig. 4.1.3C). In addition, Bac-10 administered 
during the dark phase reduced sleep fragmentation (defined as the occurrence of 
waking episodes < 16 sec per hour of sleep) compared to corresponding baseline value 
(43.1 ± 3.9 vs. 83.9 ± 4.3, respectively; p<0.001, paired t-test) or to the saline treatment 
(40.9 ± 5.3 vs. 16.9 ± 12.1, respectively; p<0.01, unpaired t-test; values represent 
difference between treatment and corresponding baseline). Finally, we further found 
that REM sleep was enhanced during the dark phase only, compared to the 
corresponding baseline and saline values (p<0.05; Table 4.1.1 and Fig. 4.1.3A).  
 
 
 
Drug 
 Wakefulness NREM sleep REM sleep 
BL Treatment BL Treatment BL Treatment 
Bac-10 
L 125.14±10.82 110.53±15.27 230.44±23.37 246.1±19.64* 58.34±5.95 57.3±4.45 
D 323.18±7.22 220.08±13.76** 100.86±14.57 192.29±19.19** 19.56±4.41 31.22±3.82* 
GHB-150 
L 195.83±12.53 173.79±10.18 337.59±12.49 357.34±10.09 77.11±8.69 79.40±7.81 
D 378.11±20.21 361.49±23.02 196.76±17.81 207.34±18.25 34.03±6.33 40.07±5.73 
GHB-300 
L 195.97±13.42 180.72±11.20 307.40±7.22 313.41±4.33 59.33±5.73 68.51±6.18 
D 359.27±21.03 330.79±20.02 205.97±12.22 233.00±10.35 48.57±9.29 49.99±4.54 
 Saline 
L 236.19±12.33 229.66±13.89 347.90±10.38 346.20±13.25 75.91±4.98 84.14±5.04* 
D 432.84±24.50 422.04±15.93 195.27±21.39 206.54±13.81 31.89±3.93 31.41±3.69 
 
Table 4.1.1 Effects of Bac and GHB on vigilance states  
Amount of wakefulness, NREM sleep and REM sleep (in minutes) following Baclofen (Bac), GHB and 
saline administration during the light (L) and dark (D) phase. The amount of vigilance states was 
computed for the period after the end of the non-physiological vigilance states and compared with 
the corresponding time-matched baseline (BL) values. Rats were assigned to four treatment groups: 
Bac 10 mg/kg (Bac-10, n = 6), GHB 150 mg/kg (GHB-150, n = 6), GHB 300 mg/kg (GHB-300, n = 5) 
and saline (n = 6). Asterisks indicate differences between BL and treatment: *p<0.05, **p<0.001, 
paired t-test. 
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Figure 4.1.3 Effect of baclofen 10 mg/kg (Bac-10) on vigilance states.  
A. Amount of wakefulness (Wake), NREM sleep (NREMs) and REM sleep (REMs; in minutes) 
following Bac-10 (n = 6) administration during the light and dark phase compared to the saline 
treatment (n = 6). Mean ± SEM values were computed as a difference between treatment and 
corresponding baseline (BL) for the period after the end of the non-physiological vigilance states. 
Bac-10 vs. saline: °p<0.1, *p<0.05, **p<0.005, unpaired t-test. B. Number and duration (in minutes) of 
NREM sleep episodes following Bac-10 administration during the light and dark phase (baseline 
comparison). Mean ± SEM values were computed as a difference between treatment and 
corresponding time-matched BL for the period after the end of the non-physiological vigilance states. 
Treatment vs. BL: *p<0.05, **p<0.01, ***p<0.0001, paired t-test. C. Number and duration (in minutes) 
of NREM sleep episodes following Bac-10 and saline administration during the light and dark phase 
(saline comparison). Values were computed as a difference between treatment and corresponding 
time-matched BL for the period after the end of the non-physiological vigilance states. Treatment vs. 
saline: °p<0.1, *p<0.01, unpaired t-test. 
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EEG spectra and slow-wave activity (SWA) in NREM sleep. Interestingly, we found 
that Bac-10 administration induced prominent changes in the EEG spectra during NREM 
sleep. EEG power density in NREM sleep was increased significantly above 
corresponding time-matched saline values in the 2.25-5.5 and 10.75-14.75 Hz frequency 
bands during both the light and dark phase (p<0.05, unpaired t-test; Fig. 4.1.4A). 
Moreover, power increase was significantly higher after drug injection in the dark phase 
compared to the one in the light phase in the frequencies above 3.25 Hz (p<0.05, paired 
t-test; data were normalised to the 12-h baseline light phase; not shown). In waking, 
significant reduction of EEG power was observed after Bac-10 administration compared 
to saline in the dark phase (1-20.5 Hz; Fig. 4.1.4B). No such effect was observed in the 
light phase. Again, Bac administration induced stronger power reduction during the 
dark phase compared to the light phase in the frequencies between 1.25-6.75 and 8.25-
18.25 Hz (p<0.05, paired t-test; not shown). Bac-10 also affected EEG activity during 
REM sleep (Fig. 4.1.4C). It enhanced power density in theta (6.5-8.75 Hz) and beta 
(above 20.75 Hz) frequencies in the dark phase compared to saline. The light-dark 
power difference was found in the frequencies 6.75-7.5 Hz (p<0.05, paired t-test; not 
shown). 
Further we show that Bac-10 increased sleep intensity based on the analysis of 
the time course of SWA (0.75-4 Hz) in NREM sleep. SWA was enhanced above the saline 
level during first two hours after light or dark Bac-10 injection (Fig. 4.1.4D). The Bac-10 
effect was stronger during the dark phase (‘phase’ p<0.05, Tukey-Kramer after mixed 
ANOVA factor ‘phase’ F(1,15)=5.36, p=0.0351; not shown).  
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Figure 4.1.4 Effect of baclofen 10 mg/kg (Bac-10) on EEG spectra.  
EEG power density in NREM sleep (A), wakefulness (B) and REM sleep (C) following Bac-10 (n = 6) 
administration during the light (filled circles) and dark phase (open circles). Power in each frequency 
bin after Bac-10 or saline treatment (n = 6) was first normalised to the corresponding mean 12-h 
light or dark baseline value of the same bin. Thereafter Bac-10 values were expressed as percentage 
of power after saline treatment. The curves connect mean values ± SEM computed for the period 
after the end of the non-physiological vigilance states. D. Time course of slow-wave activity (SWA) in 
NREM sleep following Bac-10 administration during the light (filled circles) and dark phase (open 
circles). Mean ± SEM 1-h values were first expressed as percentage of the corresponding 12-h light or 
dark baseline SWA in NREM sleep and then as percentage of SWA in NREM sleep after saline 
treatment. Differences between Bac-10 and saline during the light and dark phase are indicated by 
black and white triangles, respectively; orientation of the triangles points to the direction of the 
difference: p<0.05 (unpaired t-test following significant ANOVA). 
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Effects of GHB on behaviour, vigilance and EEG 
Behaviour and vigilance states. We then studied the effect of GHB administration on 
sleep-wake behaviour using two different doses (150 mg/kg and 300 mg/kg). We found 
that administration of GHB-300 resulted in a similar behavioural response as Bac-10. 
GHB-150 did not affect animal behaviour (rats remained awake, responded to stimuli 
and moved around the cage). Similar to Bac-10, GHB-300 induced abnormal, 
hypersynchronous EEG pattern (Fig. 4.1.2C). GHB-150 administration was followed by 
bursts of hypersynchronous slow waves appearing irregularly. Therefore, our results 
suggest that GHB induced behavioural state distinct from physiological sleep or 
wakefulness. The duration of non-physiological states depended on the dose applied. 
The states lasted 50 ± 10 and 51 ± 5 min after GHB-150 (light and dark phase, 
respectively) and 97 ± 6 and 46 ± 19 min after GHB-300. 
When acute effects of the drugs on behaviour and EEG vanished, normal vigilance 
states could again be determined. Thus, long-term effects of the drugs on vigilance states 
and EEG spectra were evaluated after the termination of the non-physiological ”drug-
induced” state. We found that GHB had no major effect on the amount of NREM sleep, 
REM sleep or wakefulness (Table 4.1.1).  
EEG spectra and SWA in NREM sleep. We found that GHB application increased EEG 
power density in NREM sleep in the frequencies encompassing SWA range. However, 
significance was reached only in the dark phase after GHB-150 (Fig. 4.1.5A) and in the 
light phase after GHB-300 administration (Fig. 4.1.5B). Both doses of GHB affected 
waking EEG power in the dark phase. GHB-150 inhibited power only in the low 
frequencies (Fig. 4.1.5A), while the power in the almost entire frequency range was 
reduced by GHB-300 (Fig. 4.1.5B). GHB had no effect on waking spectra during the light 
phase. REM sleep EEG spectrum was increased in 7.75-9.5 Hz after GHB-150 
administered in the dark phase (Fig. 4.1.5A). Minor light-dark differences in the EEG 
power were observed in the frequencies encompassing 4-4.25 Hz in NREM sleep, 4.5-
6.25 and 8.75-13.25 in REM sleep and 5.25-6.5 in waking (p<0.05, paired t-test) after 
GHB-300 injections (not shown). 
Recovery from drug effects was also assessed at the level of delta power in NREM 
sleep. Significant increase of SWA in NREM sleep was observed after GHB-300. SWA was 
above saline values during first 1-h interval following drug administration in the light 
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phase (p<0.05; Fig. 4.1.5C). GHB-150 had no significant effect on sleep intensity (not 
shown).  
 
Figure 4.1.5 Effect of GHB 150 mg/kg (GHB-150) and 300 mg/kg (GHB-300) on EEG spectra.  
A. EEG power density in NREM sleep, wakefulness and REM sleep following GHB-150 (n = 6) 
administration during the light (filled circles) and dark phase (open circles). B. EEG power density in 
NREM sleep, wakefulness and REM sleep following GHB-300 (n = 5) administration during the light 
(filled circles) and dark phase (open circles). Power in each frequency bin after GHB-150, GHB-300 or 
saline treatment (n = 6) was first normalised to the corresponding mean 12-h light or dark baseline 
value of the same bin. Thereafter GHB-150 or GHB-300 values were expressed as percentage of 
power after saline treatment. The curves connect mean values ± SEM computed for the period after 
the end of the non-physiological vigilance states. Differences between GHB-150 or GHB-300 and 
saline treatment during the light and dark phase are indicated by black and white triangles, 
respectively; orientation of the triangles points to the direction of the difference: p<0.05 (unpaired t-
test following significant ANOVA). C. Time course of slow-wave activity (SWA) in NREM sleep 
following GHB-300 administration during the light (filled circles) and dark phase (open circles). 
Mean ± SEM 1-h values were first expressed as percentage of the corresponding 12-h light or dark 
baseline SWA in NREM sleep and then as percentage of SWA in NREM sleep after saline treatment. 
Difference between GHB-300 and saline during the light phase is indicated by black triangle (p<0.05, 
unpaired t-test following significant ANOVA). 
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DISCUSSION 
Our data show that Bac and GHB robustly altered behaviour, vigilance states and EEG 
frequencies in rats. In particular, pharmacological manipulation resulted in a 
remarkable increase of EEG power in NREM sleep below 5 Hz after the termination of 
the drug state, pointing to the ability of the drugs to stimulate mechanisms generating 
EEG NREM sleep oscillations. EEG power in NREM sleep in the higher frequencies was 
also enhanced by both drugs. Moreover, we show for the first time that circadian time of 
Bac administration affected the response of the rats to the drugs. Specifically, treatment 
at the beginning of the dark phase induced larger changes in vigilance states and EEG 
spectra. Our results confirm and extend previous studies investigating the effects of Bac 
and GHB on changes in sleep and EEG pattern in mice (Meerlo et al., 2004, Vienne et al., 
2010). 
In animals, like in humans sleep is homeostatically regulated and the EEG SWA in 
NREM sleep is used as an indicator of sleep intensity (Borbely, 1982). Our analysis 
showed that Bac and both doses of GHB increased NREM sleep intensity after the end of 
the drug effect. Pharmacological manipulation affected not only EEG, but also led to the 
increase of sleep duration and consolidation. We cannot exclude that the increase of 
sleep and its intensity were a consequence of prolonged drug-induced state, during 
which sleep pressure continued to accumulate. The increase of SWA following Bac-10 
was comparable to the increase observed after 6-h sleep deprivation (Vyazovskiy et al., 
2007). However, drug-induced states were relatively short and lasted on average < 4 h. 
Moreover, duration of the drug state did not predict the SWA increase (Bac, n = 12: 
r=0.11, n.s.). Therefore, it is unlikely that “drug-induced” state was responsible for the 
increased sleep intensity observed after the state termination.  
NREM sleep EEG changes were not restricted to the low frequencies. Thus, Bac-
10 enhanced power density in the frequency range encompassing spindles (10.5-21.5 
Hz), that might point to the increased EEG synchronization within the thalamo-cortical 
circuit (Terrier and Gottesmann, 1978). GHB-300 reduced power in the frequencies 
between 6.5-8.75 Hz. 
It is well known that rodents, in contrast to humans, have a polyphasic sleep-
wake pattern. Thus, rats exhibit more sleep during the light phase. Moreover, SWA in 
NREM sleep is usually high at the beginning of the light phase and reaches its nadir 
during the dark phase. In this study we applied Bac and GHB at two circadian time 
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points, which are characterised by high and low sleep pressure, respectively. Our data 
indicate that drugs administration during low sleep pressure conditions induced 
stronger changes in sleep and EEG power in NREM sleep. In contrast, treatment at the 
beginning of the light phase was less effective, probably due to a ceiling effect. Sleep 
consolidation (i.e. duration and frequency of NREM sleep episodes) was affected 
differently in the light and dark phase (Fig. 4.1.3B, C). The timing of drug administration 
influenced also EEG spectra. Light-dark differences were more prominent in waking 
EEG. Both drugs reduced EEG power in the dark phase (Figs. 4.1.4B and 4.1.5A, B).  
Pharmacokinetics of the drugs might depend on the circadian phase and/or the 
level of animal activity. Indeed, there are data showing that kinetics can be modified 
according to the time of drug administration (Baraldo, 2008). Moreover, faster 
metabolism and, therefore, more transient effect of the drug are expected during the 
activity phase. That was not the case in our study. In addition, fluctuations in the level of 
neurotransmitters might play a role. Hence, it is important to consider intrinsic sleep 
need as well as drug kinetics during drug application in experimental and therapeutic 
conditions. 
Consistent with previous studies in mice (Meerlo et al., 2004, Vienne et al., 2010), 
we showed that both GHB and Bac induced a drug state distinct from physiological sleep 
also in rats. Several criteria defining normal physiological sleep (Borbely and Tobler, 
1989) were affected by the drugs. Specifically, rats consistently displayed unnatural 
body posture and revealed atypical hypersynchrony in the cortical EEG signal. The 
magnitude and duration of the observed effects depended on the drug and changed in a 
dose-dependent manner. The differences in the level of drug response between GHB and 
Bac are consistent with the half-life of the drugs in rats (60 min for GHB (Snead, 1977, 
Kueh et al., 2008) and 3-4 h for Bac (Lal et al., 2009)).   
In our study GHB treatment had no effect on the amount of vigilance states. This 
is in line with results shown previously by Meerlo et al. (Meerlo et al., 2004). In contrast, 
recent study in mice reported decreased NREM and REM sleep in the light period 
following 300 mg/kg of gamma-butyrolactone, a prodrug of GHB (Vienne et al., 2010). 
Godschalk et al. (Godschalk et al., 1977) showed that doses of 50-100 mg/kg GHB 
increased SWS, while dose of 200 mg/kg induced EEG hypersynchrony and behavioural 
arrest. Studies investigating dose- and concentration-response relationship of GHB 
applied intravenously reported lack of the effect at 150 (Van Sassenbroeck et al., 2001) 
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or 200 mg/kg (Felmlee et al., 2010). Therefore, literature data describing the effects of 
GHB on sleep are contradicting. The discrepancy might be related to experimental 
conditions, including injection time, amount of data entering the analysis, route of drug 
administration, species.  
Interestingly, atypical behavioural state and changes in EEG produced by Bac and 
GHB-300 have different time course. Thus, abnormal EEG pattern appeared few minutes 
after drug administration and lasted up to 97 min for GHB-300 or 5.5 h for Bac-10, 
greatly exceeding behavioural response (40-70 min for both drugs). Drug response 
might depend on absorption, distribution and elimination rates. After reaching peak 
plasma concentration the behavioural effects gradually dissipate, while longer-lasting 
effects in the brain can remain. Therefore, lower dose of GHB (150 mg/kg) was 
insufficient to cause any visible behavioural effects, but sufficient to induce changes in 
EEG. 
Both drugs affected EEG power density in REM sleep. Significant increase of 
power in the theta frequency range was observed after GHB-150 (7.75-9.5 Hz) and Bac-
10 (6.5-8.75 Hz) administration in the dark phase (Figs. 4.1.5A and 4.1.4C). There is 
evidence that median raphe nucleus (MRN) may serve to desynchronize hippocampal 
EEG and thus to block theta rhythm (Vertes, 1981). Bac, through GABAB receptors, might 
suppress firing of serotonergic neurons in the raphe nucleus (Colmers and Williams, 
1988, Innis et al., 1988) and promote theta rhythms generation. Indeed, Bac infused into 
the serotonin-containing MRN promoted theta rhythm in anaesthetised rats (Varga et 
al., 2002, Li et al., 2005a). A number of studies reported increased serotonergic activity, 
including firing rate (Inouye and Kawamura, 1979), c-Fos immunoreactivity (Janusonis 
and Fite, 2001) and serotonin release (Kalen et al., 1989, Rueter and Jacobs, 1996) 
during dark phase. Interestingly, in our study enhanced theta power was present only 
during the dark phase. 
In addition, GHB and Bac may affect other monoaminergic systems. Thus, both 
drugs inhibited noradrenergic neurons in locus coeruleus (Osmanovic and Shefner, 
1988, Szabo et al., 2004) and dopaminergic neurons in ventral tegmental area (Madden 
and Johnson, 1998, Cruz et al., 2004) in rats. It has been suggested that a decrease of 
dopaminergic or noradrenergic transmission induces an increase of EEG spectral power 
(Sebban et al., 1999), while stimulation of noradrenergic neurons blocks slow cortical 
oscillations (Steriade et al., 1993). Moreover, a number of studies reported daily 
  
46 
rhythmicity in the activity of those systems with the peak in the middle of the dark 
phase (Nagayama, 1999, Feenstra et al., 2000), which may influence the action of both 
tested drugs. 
In conclusion, our data show that 1) GHB and Bac induce a non-physiological 
resting state and affect vigilance, EEG and behaviour in rats, 2) these effects are 
dependent on the time of drug administration, 3) Bac, but not GHB, has sleep-promoting 
properties. It is possible that observed effects may be related to a complex mechanism, 
engaging multiple neurotransmitter systems. The effects of sleep promotion on 
functional recovery after stroke, what actually motivated this study, could now be tested 
with baclofen in rats.  
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ABSTRACT 
 
Sleep disruption in the acute phase after stroke has detrimental effects on recovery in 
both humans and animals. Conversely, the effect of sleep promotion remains unclear. 
The aim of this study was to investigate the effect of baclofen (Bac), considered a sleep-
promoting drug, on stroke recovery in a rat model of focal cerebral ischemia (isch).  
Rats, assigned to three experimental groups (Bac/isch, saline/isch or Bac/sham), 
were injected twice daily for 10 consecutive days with Bac or saline starting 24 h after 
induction of stroke. Sleep and functional recovery were assessed by EEG recordings and 
single pellet reaching test (SPR), respectively. To identify potential underlying 
mechanisms, axonal sprouting and neurogenesis were evaluated. 
Repeated Bac treatment after ischemia increased NREM sleep amount during the 
dark phase. Moreover, ischemic rats treated with Bac performed significantly better in 
the SPR test than saline-treated animals. Axonal sprouting in the ipsilesional motor 
cortex and striatum, and neurogenesis in the peri-infarct region were significantly 
increased in the Bac/isch group.  
In conclusion, delayed repeated Bac treatment after stroke increased NREM sleep 
and promoted both neuroplasticity and functional outcome. These data support the 
hypothesis of the role of sleep as a modulator of post-stroke recovery. 
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INTRODUCTION 
Ischemic stroke is one of the most prevalent neurological conditions and a leading cause 
of death and long-term disability worldwide (Duncan, 2002, Burns et al., 2009). Despite 
progress made in understanding the mechanisms involved in neuronal damage during 
ischemia, limited advances have been reached in developing effective treatments for 
stroke patients (Ernst, 1990, Ottenbacher and Jannell, 1993). Spontaneous partial 
recovery after stroke is associated with neuronal plasticity mechanisms. Data from both 
patients and animal models showed a remodelling of neuronal networks in the 
hemisphere affected by stroke as well as recruitment of additional circuits from the 
contralesional hemisphere (Wiessner et al., 2003, Gerloff et al., 2006). Therefore, 
methods inducing or enhancing neuronal plasticity processes in the lesioned brain area 
may represent a novel effective therapeutic strategy for stroke. 
There is growing evidence suggesting an important role of sleep in facilitating 
brain plasticity (Tononi and Cirelli, 2003, Vassalli and Dijk, 2009). Changes in sleep and 
sleep electroencephalogram (EEG) may reflect changes in connectivity within cortical 
neuronal network, but also drive changes in synaptic strength (Huber et al., 2004, 
Vyazovskiy et al., 2009). Sleep deprivation (SD) impairs induction and/or maintenance 
of long-term potentiation (LTP) (e.g. (McDermott et al., 2003)), a basic mechanism 
thought to underlie neuronal plasticity and memory formation, whereas sleep 
oscillations induced LTP (Chauvette et al., 2012). Moreover, it has been shown that 
plasticity-related genes and proteins display differential expression in sleep, 
wakefulness and following SD (Cirelli et al., 2004).   
There is accumulating evidence suggesting an important role for sleep in stroke 
recovery. Manipulation of sleep after ischemia may in fact affect stroke outcome. 
Disruption of sleep during acute and subacute phase of stroke aggravated brain damage 
(Gao et al., 2010) and impeded functional recovery in rats (Zunzunegui et al., 2011). On 
the contrary, administration of gamma-hydroxybutyric acid (GHB), considered a sleep-
promoting drug, immediately after reperfusion accelerated motor function recovery in 
mice (Gao et al., 2008). Furthermore, a physiological enhancement of sleep (following 
previous sleep deprivation) occurring immediately after stroke induction, was also 
associated with a reduction of brain damage (Cam et al., 2013). Sleep may, therefore, 
play a dual beneficial role in brain repair, fostering neuroprotection in the acute phase 
and enhancing neuroplasticity in the delayed phase after stroke. 
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The aim of the current study was to investigate the effect of sleep enhancement 
on brain repair and functional recovery after the acute phase of ischemic stroke. We 
hypothesized that induction of sleep or synchronized neuronal activity would facilitate 
motor function recovery and brain repair mechanisms in a rat model of focal cerebral 
ischemia. Considering our strong interest in translational approaches, we decided to use 
baclofen (Bac), a GABAB receptor agonist which is known to promote sleep in humans 
(Darbari et al., 2005). Our group has recently shown that Bac also increases non-rapid 
eye movement (NREM) sleep duration in rats (Hodor et al., in review).  
 
 
METHODS 
Animals 
Adult male Sprague-Dawley rats (n = 53; Harlan Laboratories Netherlands, Charles-
River Germany), 318 ± 17g at the time of surgery, were maintained on a 12-12 h light-
dark cycle at 22 ± 0.5°C ambient temperature. They were kept individually in Macrolon 
cages and provided with food and water ad libitum, except food restriction during 
behavioural training. The experiments were carried out with governmental approval 
according to local guidelines for the care and use of laboratory animals at the University 
Hospital Zürich, Switzerland. 
 
Experimental protocol 
Two separate experiments were performed. In Experiment 1 (Fig. 4.2.1A), rats were 
implanted with EEG and electromyogram (EMG) electrodes. Animals were then 
subjected to focal cerebral ischemia (isch) or sham surgery and assigned to one of the 
three experimental groups: Bac/isch (n = 6), saline/isch (n = 7) or Bac/sham (n = 4). 
Baclofen (Sigma-Aldrich, Switzerland; 10 mg/kg) was diluted in saline (0.9% NaCl) to 
obtain 3 mg/ml working solution. The drug was administered intraperitoneally (i.p.) 24 
h after surgery and then twice daily (1 h after light onset and offset) for 10 consecutive 
days. Sleep was recorded during baseline preceding surgery and on day 2, 6 and 11 after 
surgery. All animals were decapitated one day after the last injection and their brains 
were collected for histological analysis. 
In Experiment 2 (Fig. 4.2.1B), rats were trained in a single pellet reaching task 
(SPR) for ca. 25 days. During training the preferred paw was identified for every rat. 
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Cerebral ischemia or sham surgery was performed, when animals reached a stable level 
of performance. Thereafter, rats were subdivided into three groups Bac/isch (n = 14), 
saline/isch (n = 14) and Bac/sham (n = 8) and subjected to the same pharmacological 
protocol as in Experiment 1. Motor function was assessed one day after surgery before 
the first drug injection and then weekly starting on the day after the end of the drug 
administration (days 12, 19, 26, 33 and 40 after surgery).  
Proliferation marker, 5-bromo-2′-deoxyuridine (BrdU, Sigma Aldrich, St. Louis, 
MO;  50 mg/kg) (Wojtowicz and Kee, 2006), incorporating into DNA during cell division, 
was administered for 10 days (2 h after light onset, i.p.), and followed Bac or saline 
injections. BrdU was diluted in saline (concentration 10 mg/ml).  
The anterograde tracer biotinylated dextran amine (BDA, 10%; MW,10,000 Da, 
Molecular Probes, Eugene, OR, USA; diluted in 0.01M phosphate buffer) (Reiner et al., 
2000), used to evaluate axonal sprouting (Carmichael and Chesselet, 2002, Zunzunegui 
et al., 2011), was micro-injected at two locations into the motor cortex contralateral to 
the lesion side (stereotaxic coordinates: +/-1 mm AP, 1 mm ML, 3 mm DV from the 
skull). All rats belonging to the Experiment 2 received a total volume of 1 μl of tracer 
(0.5 μl of each injection, over 10 minutes) six weeks after surgery. Two weeks later rats 
were sacrificed and brains were collected for further evaluations. 
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Figure 4.2.1 Design of the experiments  
A. In Experiment 1 rats were implanted with EEG/EMG electrodes and 11 days later subjected to 
ischemia (isch) or sham surgery. 24 h after surgery animals were treated with the drug (10 mg/kg 
baclofen, Bac, or saline, Sal), and then twice daily for ten days. EEG and EMG were recorded during a 
24-h baseline (BL) day and on days 2, 6 and 11 following isch/sham surgery. Three treatment groups 
were designed: Bac/isch (n = 6), Sal/isch (n = 7) and Bac/sham (n = 4). B. In Experiment 2 rats were 
trained in the single pellet reaching (SPR) task for 3 - 4 weeks preceding isch or sham surgery. 24 h 
after surgery rats were treated with Bac or Sal, and then twice daily for ten days. All rats received 
also bromodeoxyuridine (BrdU) injection for ten days. SPR performance was assessed over 3 days 
preceding surgery (baseline) and on days 1, 12, 19, 26, 33 and 40 following surgery. Forty one day 
after surgery all rats received microinjection of biotinylated dextran amine (BDA) and were perfused 
two weeks later. Three treatment groups were designed: Bac/isch (n = 14), Sal/isch (n = 14) and 
Bac/sham (n = 8). 
 
EEG implantation and recording 
Rats were implanted epidurally with EEG and EMG electrodes under deep anaesthesia 
(2% isoflurane in 30% O2 and 70% N2O). Four gold-plated mini-screws were positioned 
in the skull over the motor cortex of the right and left hemispheres (+/-2 mm to bregma, 
2 mm lateral to midline). Electrodes were connected to stainless steel wires and fixed to 
the skull with dental cement. Two gold wires were inserted bilaterally in the neck 
muscles for EMG recording. At least 8-10 days were allowed for recovery. 
EEG and EMG were sampled at 200 Hz. Signals were amplified, filtered and 
analog-to-digital converted. Hardware EMBLA and software Somnologica-3 (Medcare 
Flaga, Iceland) were used. Activity in the 50 Hz band was discarded from the analysis 
because of power line artifacts. The EEG was subjected to a discrete Fourier 
transformation yielding power spectra (range: 1–25 Hz; frequency resolution: 0.25-Hz 
bins; time resolution: consecutive 4-sec epochs; window function: hamming). 
Three vigilance states - NREM sleep, REM sleep and wakefulness - were visually 
scored according to standard criteria at 4-sec epochs (Tobler et al., 1997). In addition to 
these three conventional vigilance states we introduced a new state, distinct from 
physiological sleep or wakefulness, which was observed after Bac administration. This 
state was characterised by atypical behaviour and abnormal hypersynchronous EEG 
pattern (“drug-induced state”), as described previously (Hodor et al., in review). The 
state lasted 195.5 ± 7.6 and 197 ± 8.3 min in the Bac/isch group (light and dark phase, 
respectively), and 103.5 ± 32 and 189.1 ± 11.5 min in the Bac/sham group. Epochs were 
assigned to a specific vigilance state when more than half of the epoch fulfilled the 
criteria for that state. Epochs containing EEG artifacts were identified and excluded from 
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subsequent spectral analysis in both derivations (25% of recording time, most of them 
(17%) occurred during wakefulness). 
 
Induction of focal cerebral ischemia 
Stroke was induced by the 3 vessel occlusion method (3Vo) with permanent occlusion of 
the distal middle cerebral artery (MCA) and the ipsilateral common carotid artery (CCA), 
superimposed by temporal occlusion of the contralateral CCA under general anaesthesia 
with 2% isoflurane (Chen et al., 1986, Zunzunegui et al., 2011). A small piece of the skull 
overlying the MCA was removed and the dura was retracted. The MCA and its three main 
branches were occluded by bipolar electrocoagulation. The CCA ipsilateral to the 
occluded MCA was ligated permanently with a 4-0 silk suture, whereas the contralateral 
CCA was temporarily occluded for 60 min with an aneurysm clip. Rectal temperature 
was maintained between 36.5 ± 0.5°C by a warm lamp during the surgery. Sham-
operated rats were subjected to the same procedure except for occlusion of the MCA and 
CCA. Both ischemia and sham surgeries were performed on the hemisphere 
contralateral to the preferred forelimb assessed by SPR task. 
 
Single pellet reaching (SPR) task 
SPR task was used to assess fine motor skills (Gharbawie et al., 2005a). Rats had to use 
their preferred forelimb to retrieve a food pellet located in a well outside the test 
chamber (Zunzunegui et al., 2011). Briefly, animals were placed in a clear Plexiglas box 
(41×27×37 cm) with a vertical slit (1×15 cm) placed in the middle of the front wall, 1 cm 
above the floor. A 2-cm wide shelf with small wells was mounted in the front of the slit, 
but outside the box wall. Animals were trained to reach a food pellet (45 mg dustless 
precision pellet, Bio-Serv, Frenchtown, NJ, USA) placed in the well on the shelf. Rats 
received daily training sessions consisting of 50 pellets for 3-4 weeks. A pellet was 
placed in the well on the side contralateral to the preferred paw. A single reaching 
attempt was permitted. Reaching attempts were classified as successful or failed. In the 
successful attempt the rat was expected to make a single reach, grasp the pellet from the 
well, bring it to the mouth and eat it. During the test sessions before and after surgery 
rats were given 50 pellets and the session ended when rats made 50 attempts or when 
15 min elapsed. Success rate was computed as the percentage of successfully obtained 
pellets out of 50 possible attempts. The baseline (BL) performance was computed as the 
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average of the three days immediately preceding surgery. Improvement in post-stroke 
motor performance was computed as a difference in success rate between days 40 and 1 
after ischemia. 
To increase motivation all animals underwent a food restriction schedule with 20 
grams of chow per day during the training weeks and at the days preceding the test 
sessions. During this time rats were maintained at 95% of their normal body weight. 
 
Tissue collection 
Two weeks after BDA administration rats were deeply anaesthetised and perfused 
transcardially with ice-cold 4% PFA in phosphate buffered saline (PBS). Brains were 
removed, post-fixed in PFA for 2 h and cryoprotected in 15 and 30% sucrose in the 
ascending manner. The tissue was stored at -80°C for further evaluations.  
 
Analysis of lesion volume and corpus callosum thickness 
To determine lesion size and corpus callosum thickness, 40 μm thick coronal sections 
were cut with a cryostat at six predefined levels: 2.7 (L1), 1.7 (L2), 0.7 (L3), −0.3 (L4), 
−1.3 (L5), and −2.3 (L6) mm to bregma (Paxinos and Watson, 2007). Brain sections were 
then stained with cresyl violet and digitized. Measurements were done with ImageJ 
(NIH, Bethesda, MD, USA). Brain damage was computed on one section for each level  as 
a difference between intact hemisphere and the non-lesioned area of the ischemic 
hemisphere. Lesion volume was estimated by multiplying obtained brain damage values 
by the size of each level (section thickness plus distance between levels). The corpus 
callosum thickness was measured using coronal sections from L6 level. 
 
Immunohistochemistry 
For detection of BDA, free-floating brain sections were incubated overnight with avidin-
biotin-peroxidase complex (Elite ABC kit, Vector Laboratories, Burlingame, CA, USA) and 
revealed with 3,3’-diaminobenzidine (DAB, Sigma) (Zunzunegui et al., 2011). The 
sections were digitized and the area of BDA labeled axons was quantified by 
determining the number of pixels above the intensity gray scale threshold using ImageJ 
(NIH, Bethesda, MD, USA) as previously described (Carmichael and Chesselet, 2002). 
Briefly, the mean surface area of BDA labeled axons was measured in the primary motor 
cortex and striatum at the levels L2-L4 of coronal sections. Ratios between ipsilesional 
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and contralesional cortical surface areas (corresponding to the corticocortical 
projections) and between ipsilesional striatal and contralesional cortical areas 
(corresponding to the corticostriatal projections) were used as an index of axonal 
sprouting. For each rat 2 adjacent sections were averaged on each level (n = 9, n = 10, n 
= 7 for corticocortical and n = 7, n = 7, n = 6 for corticostriatal in the saline/isch, 
Bac/isch and Bac/sham group, respectively). Ratios closed to zero indicated a low BDA 
penetration from the contra- to the ipsilesional side and, therefore, limited axonal 
sprouting.  
Double immunofluorescence staining with the antibody against BrdU together 
with antibodies against specific cell type marker was used to detect cell proliferation 
and to assess the type of proliferating cells. Free-floating sections were incubated in 2M 
HCl for 2 h at room temperature (RT) to denaturate DNA and then washed four times in 
PBS pH=7.4. After preincubation in blocking solution (0.01M PBS containing 2% 
appropriate normal sera and 0.3% Triton-X), sections were incubated overnight at +4°C 
with the rat anti-BrdU antibody (1:200, Abcam, Cambridge, UK) and one of the following 
antibodies for a specific cell type marker: mouse anti-NeuN (1:200, Millipore, Billerica, 
MA, USA; marker for neurons), rabbit anti-glial fibrillary acidic protein (GFAP, 1:200, 
Dako, Carpinteria, CA, USA; marker for astrocytes) or rabbit anti-ionized calcium binding 
adapter molecule 1 (Iba1, 1:600, Wako Chemicals, Osaka, Japan; marker for microglia). 
Sections were then incubated for 1.5 h at RT with the fluorophore-conjugated secondary 
antibodies Alexa Fluor-488 (green; for detection of BrdU) or Cy3 (red; for detection of 
other markers) (1:200, Jackson Immunoresearch, West Grove, PA, USA) against the 
appropriate host species of the primary antibodies. Finally, sections were rinsed three 
times with PBS, mounted on gelatin subbed slides (Southern Biotechnology Association, 
Inc, USA) and cover-slipped. 
 
Cell counting and microscopy analysis 
The number of BrdU positive (+), NeuN+/BrdU+, GFAP+/BrdU+ and Iba1+/BrdU+ cells 
were quantified in the peri-infarct region of ischemic animals and in the corresponding 
cortical region of sham animals using the optical fractionator probe (Stereo Investigator 
version 8.2, MicroBrightField Inc., Williston, VT, USA) at 40x magnification on a 
fluorescence microscope equipped with a motorized x-y stage (Zeiss Axio Imager Z1, 
Germany; 20x/0.5 EC Plan-Neofluar objective). The peri-infarct area was outlined on a 
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10x magnification using the tracing function of Stereo Investigator. Several parameters 
were then determined on optical fractionator: counting frame (200 x 200 μm; x–
y plane), optical dissector height (27-36 μm; z plane), distance between sampling 
regions (600 μm in x and y-direction) and the grid size. A computer driven motor stage 
allowed to analyze sections at each of the counting frame location under a 40x 
magnification. This procedure provided unbiased stereological quantification, because 
once the region of interest was outlined, sampling sites were evenly and randomly 
distributed throughout the marked region. Quantification was performed at levels L2 
and L3 and averaged on 2 sections per animal (n = 7 per ischemic groups, n = 6 per sham 
group). The data are presented as the average of cell number per mm2. All histological 
and immunohistochemical analyses were determined in a blinded way.  
 
Statistical analysis 
Effects of Bac treatment and time on motor performance in the SPR task were evaluated 
by a repeated measures ANOVA (SAS software, SAS Institute, Cary, NC, USA). Effects of 
treatment on sleep, neurogenesis, axonal sprouting, corpus callosum thickness and brain 
damage were evaluated by one-way ANOVA. Post-hoc paired and unpaired t-tests, 
Wilcoxon and Kruskal-Wallis or Tukey-Kramer test for multiple comparisons were 
performed if the results of the ANOVA reached statistical significance (p<0.05). All 
provided values are means ± SEM. Pearson correlation coefficients were calculated 
between SPR performance and BDA or BrdU parameters; p<0.05 was considered of 
statistical significance. 
 
 
RESULTS 
Effects of Bac on behaviour, vigilance states and EEG power spectrum 
Bac increased the amount of NREM sleep during the dark period on days 2, 6 and 11 
after stroke compared to saline administration (p<0.05, unpaired t-test; Fig. 4.2.2A). We 
found no changes in the amount of REM sleep after Bac treatment.  
EEG power spectra were affected mostly in the hemisphere ipsilateral to the 
lesion. Stroke led in fact to a significant reduction of EEG power density in NREM sleep 
in the almost entire frequency range (Fig. 4.2.2B). Thus, in the saline/isch group it was 
reduced below BL values in the frequencies > 3.75 Hz during both, light and dark phases 
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on days 2 and 6 after stroke and during light phase on day 11 (Fig. 4.2.2B left). Bac 
treatment resulted in a partial recovery of power. Hence, a significant reduction of 
power density in the frequencies > 4.75 Hz was observed only during the light phase on 
day 2 after stroke (Fig. 4.2.2B right). EEG power was below BL values in the frequencies 
between 5.75 and 7.75 Hz on days 6 and 11 (only light phase) and above 17 Hz on day 6 
(Fig. 4.2.2B right).  
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Figure 4.2.2 Effect of baclofen (Bac) or saline (Sal) treatment on NREM sleep amount 
(minutes) (A) and EEG power density in NREM sleep (B) during the light and dark phase of 
days 2, 6 and 11 after stroke.   
A. Amount of NREM sleep (mean ± SEM) was computed over the 11-h period following drug injection 
as a difference between treatment and corresponding baseline (BL) level. Δp<0.05, unpaired t-test.          
B. Power in each frequency bin after Bac or Sal treatment was normalised to the corresponding mean 
12-h light BL value of the same bin. The curves connect mean values ± SEM during the light and dark 
phase. Circles indicate differences between the treatment day and BL: p<0.05, paired t-test. 
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Effects of Bac on functional recovery 
Effects of Bac administration on the recovery of grasping ability were assessed by SPR 
task. All rats showed similar performance in the task prior to ischemia. The success rate 
of pellet retrieval was 51.14 ± 2.75 %, 51.36 ± 2.81 % and 45.50 ± 2.74 % in Bac/isch, 
saline/isch and Bac/sham groups, respectively. Rat performance dropped to zero 
immediately after stroke in both ischemic groups, but remained stable in the sham-
operated animals (Fig. 4.2.3A). Slow spontaneous recovery was observed in the 
saline/isch group in the course of the following six weeks. However, saline/isch rats 
never reached the performance level of sham-operated animals (p<0.005, Kruskal-
Wallis after rANOVA interaction ‘group’ x ‘day’ F(12,198)=7.58, p<0.0001; Fig. 4.2.3A). In 
contrast, pellet retrieval of the Bac/isch group did not differ significantly from the 
Bac/sham group starting from day 33 post-stroke. Moreover, ischemic rats treated with 
Bac had generally a higher success rate than saline-treated animals (p<0.01, Tukey-
Kramer ‘group’ after rANOVA factor ‘group’ F(2,33)=12.51, p<0.0001; Fig. 4.2.3A).  
It has been shown previously that the side of the brain lesion may affect the 
dynamics of functional recovery (Miklyaeva et al., 1993). Therefore, we investigated the 
effect of the lesion side on the success rate of pellet retrieval. Bac facilitated motor 
function recovery only in rats with right hemispheric stroke (p<0.0001, Tukey-Kramer 
‘group’ after rANOVA factor ‘group’ F(2,17)=9.68, p=0.0016; Fig. 4.2.3B). Improvement in 
performance was detected already at day 19 after surgery. No such facilitation was 
observed in rats with left hemispheric stroke (Tukey-Kramer ‘group’ n.s.; Fig. 4.2.3C). 
Moreover, both ischemic groups with left hemispheric stroke showed no significant 
difference from sham-operated animals starting from day 26 after surgery (Fig. 4.2.3C). 
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Figure 4.2.3 Effects of baclofen (Bac) or saline (Sal) treatment on motor function recovery in 
the single pellet reaching (SPR) task following brain ischemia (isch) or sham surgery:  
all rats pooled (A), rats with lesion in the right (B) or left hemisphere (C). The SPR success (number 
of successful attempts) was expressed as percentage of the total reaching attempts made (mean ± 
SEM). Triangles indicate difference between Bac/sham and Bac/isch (orange) or Sal/isch (light 
orange) groups; stars between Bac/isch and Sal/isch group: p<0.05, unpaired t-test following 
significant ANOVA. 
 
Effects of Bac on axonal sprouting 
Functional recovery can be related to neuroanatomical changes of tracts of fibers 
originating in the unlesioned cortex (Wiessner et al., 2003). Therefore, we evaluated 
axonal sprouting from neurons in the contralesional motor cortex towards the 
ipsilesional hemisphere (cortex and striatum; Fig. 4.2.4). Ratios reflecting corticocortical 
and corticostriatal projections were closed to zero in the Bac/sham rats, indicating that 
treatment did not affect axonal sprouting in the control situation (Fig. 4.2.4B). In the 
saline/isch group only the corticostriatal ratio showed a significant increase compared 
to sham values (p<0.005, Tukey-Kramer after ANOVA factor ‘group’ F(2.19)=57.10, 
p<0.0001; Fig. 4.2.4B). In contrast, Bac treatment in ischemic rats resulted in a 2-fold 
increase of both ratios compared to either saline/isch or Bac/sham group (p<0.0001, 
Tukey-Kramer after ANOVA factor ‘group’ F(2.25)=54.46 and F(2.19)=57.10, p<0.0001 for 
corticocortical and corticostriatal ratios, respectively; Fig. 4.2.4B), indicating 
pronounced axonal sprouting from contra- to ipsilesional hemisphere. Moreover, ratios 
reflecting corticocortical and corticostriatal projections correlated positively with the 
improvement in motor performance (r=0.53, p<0.01, n = 26 and r=0.47, p<0.05, n = 20, 
respectively). 
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Figure 4.2.4 Effect of baclofen (Bac) or saline (Sal) treatment on axonal sprouting (mean ± 
SEM) into the lesion-sided motor cortex and striatum following ischemia (isch) or sham 
surgery.  
A. Schematic coronal brain section illustrating site of the lesion and placement of biotinylated 
dextran amine (BDA) tracer injection. B. Quantification of corticocortical (left panel, dashed-box area 
in A) and corticostriatal (right panel, black-boxed area in A) projections stained with BDA. 
Differences between groups: *p<0.005, **p<0.0001, Tukey-Kramer following significant ANOVA. C-E: 
High-power magnification photographs from representative Sal/isch (C), Bac/isch (D) and Bac/sham 
(E) rats showing BDA traced fibers in the ipsilesional motor cortex (dash-boxed area in A). Scale 
bars, 50 μm. F. Effect of Bac or Sal treatment on stroke-induced corpus callosum atrophy (mean ± 
SEM) 12 and 55 days after isch or sham surgery . *p<0.05, unpaired t-test; ** p<0.005, ***p<0.001, 
Tukey-Kramer following significant ANOVA. 
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Effects of Bac on neurogenesis 
After stroke the peri-infarct area shows increased neuroplasticity, which allows 
sensorimotor functions remapping (Dijkhuizen et al., 2003, Cramer, 2008). In order to 
evaluate the effect of Bac treatment on neurogenesis, we assessed the number of BrdU+ 
cells in the peri-infarct region eight weeks after ischemia. Consistent with previous 
reports (Shin et al., 2008, Zunzunegui et al., 2011), we found a prominent BrdU labelling 
in both ischemic groups in contrast to sham animals, which showed a low level of cell 
proliferation. Moreover, there was a 60 % increase in the number of BrdU+ cells in the 
Bac/isch (527 ± 32 cells/mm2) compared to the saline/isch group (317 ± 24 cells/mm2; 
p<0.0001, Tukey-Kramer after ANOVA factor ‘group’ F(2.26)=59.22, p<0.0001).  
To characterise the fate of BrdU+ cells, we examined double immunostaining with 
different cell-specific markers (NeuN for neurons, GFAP for astrocytes and Iba1 for 
microglia). Quantification of double labelled cells revealed that Bac administration after 
ischemia induced a significant increase of all targeted cell types compared to both 
saline/isch and Bac/sham groups. The number of NeuN+/BrdU+, GFAP+/BrdU+ and 
Iba1+/BrdU+ cells was significantly above saline/isch values 55 days after stroke 
(p<0.0001, Tukey-Kramer after ANOVA factor ‘group’ F(2.19)=70.53, F(2.19)=74.89, and 
F(2.19)=18.11, p<0.0001, respectively; Fig. 4.2.5A). In addition, the number of newborn 
neurons, astrocytes and microglia correlated positively with the improvement in SPR 
task (r=0.71, p<0.0005; r=0.74, p<0.0005; r=0.57, p<0.01, n = 20, respectively).  
In all groups the majority of BrdU+ cells co-localized with the neuronal marker 
NeuN (Fig. 4.2.5B). The percentage of NeuN+/BrdU+ cells in both ischemic groups was 
significantly higher compared to sham-operated animals (p<0.001, Tukey-Kramer after 
ANOVA factor ‘group’ F(2.19)=12.08, p<0.05). No difference was found between the two 
ischemic groups. Interestingly, the proportion of GFAP+/BrdU+ cells was significantly 
higher in Bac/isch compared to both saline/isch and Bac/sham groups (p<0.0001, 
Tukey-Kramer after ANOVA factor ‘group’ F(2.19)=13.53, p<0.05; Fig. 4.2.5B). 
Additionally, the proportion of NeuN+/BrdU+ and GFAP+/BrdU+ cells correlated 
positively with the recovery of post-ischemic SPR success (r=0.69, p<0.001; r=0.65, 
p<0.005; n = 20, respectively). The percentage of BrdU+ cells co-expressing Iba1 did not 
differ between groups. 
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Figure 4.2.5 Effects of baclofen (Bac) or saline (Sal) treatment on cell proliferation in the peri-
infarct region 55 days after ischemia (isch) or sham surgery.  
A. Number (mean ± SEM) of newborn neurons (NeuN+/BrdU+ cells), astrocytes (GFAP+/BrdU+ cells) 
and microglia (Iba1+/BrdU+ cells) per mm2. B. Proportion of BrdU+ cells expressing NeuN, GFAP or 
Iba1 in the three experimental groups. Differences between groups: *p<0.05, **p<0.005, 
***p<0.0001, Tukey-Kramer after significant ANOVA. C. Representative confocal images of BrdU-
positive cells in the peri-infarct region (red-boxed area on the brain scheme) of Sal/isch and Bac/isch 
groups. Scale bars, 100 μm. 
 
*
**
*
NeuN GFAP Iba1
Pe
rc
e
nt
ag
e
 
o
f B
rd
U+
 
ce
lls
 
co
lo
ca
liz
e
d 
w
ith
 
o
th
e
r 
m
ar
ke
rs
0
20
40
60
80
Sal/isch 
Bac/isch 
Bac/sham 
 *
  *   ***
  ***
*
Newborn neurons
Sal/isch 
  (n=7)
Bac/isch 
  (n=7)
Bac/sham 
   (n=6)
Ne
uN
+
/B
rd
U+
 
ce
lls
 
pe
r 
m
m
2
0
100
200
300
400
500
Newborn astrocytes
Sal/isch 
  (n=7)
Bac/isch 
  (n=7)
Bac/sham 
   (n=6)
G
FA
P+
/B
rd
U+
 
ce
lls
 
pe
r 
m
m
2
0
20
40
60
80
Newborn microglia
Sal/isch 
  (n=7)
Bac/isch 
  (n=7)
Bac/sham 
   (n=6)
Ib
a1
+
/B
rd
U+
 
ce
lls
 
pe
r 
m
m
2
0
40
80
120
160
200
 ****** ***  *** *** **
*
 ***
B. C.
Sal/isch Bac/isch
A.
  
64 
 
Figure 4.2.6 Phenotype of BrdU-positive cells (representative confocal images).  
Coronal sections were double labeled (arrows) for BrdU (green) and NeuN (A), GFAP (B) or Iba1 (C) 
(red). Scale bars, 30 μm. a-c: Orthogonal reconstructions confirming double labeling in x–z (bottom) 
and y–z (right) planes. Scale bars, 10 μm. 
 
Effects of Bac on lesion volume and corpus callosum thickness 
Bac treatment had no effect on the extension of the sensorimotor cortex damage. Lesion 
size differed between Bac- and saline-treated animals neither 12 (55.5 ± 10.1 vs. 57.5 ± 
8.8 mm3, respectively; n.s.) nor 55 days after ischemia (61.8 ± 11.1 vs. 71 ± 9.6 mm3, 
respectively; n.s.). The mean volume of the right hemisphere lesion (66.8 ± 14.9 and 76.4 
± 10.9 mm3; Bac and saline group, respectively) did not differ significantly from the left 
hemisphere lesion (55 ± 17.9 and 62.4 ± 18.8 mm3). 
It has been shown that ischemia results in corpus callosum atrophy, which is 
considered to be an indirect marker of neuronal loss (Yamauchi et al., 2000). To further 
evaluate the effects of Bac treatment on the ischemic brain, we determined thickness of 
corpus callosum. Thickness of corpus callosum was reduced in the saline/isch group 
when compared to the Bac/sham group (p<001, Tukey-Kramer after ANOVA factor 
‘group’ F(2,32)=11.18, p=0.0002, n = 33; Fig. 4.2.4F). Bac treatment of ischemic rats 
decreased the atrophy of the corpus callosum significantly compared to saline treatment 
both at 12 (p<05, unpaired t-test, n = 12; Fig. 4.2.4F) and 55 days after ischemia (p<005, 
Tukey-Kramer after ANOVA factor ‘group’ F(2,32)=11.18, p=0.0002, n = 33; Fig. 4.2.4F).  
A. B. C.
a. b. c.
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DISCUSSION 
In the present study we show for the first time to our best knowledge, that 
pharmacological sleep promotion with baclofen (Bac) 1) has  beneficial impact on long-
term functional recovery after stroke in rats, and 2) this improvement in behavioural 
performance is associated with an enhancement in endogenous brain restorative 
processes, such as axonal sprouting and neurogenesis.  
Sleep has been suggested to be important during the recovery process after 
stroke. We have previously shown that sleep disruption after cerebral ischemia impairs 
functional and structural outcomes (Zunzunegui et al., 2011), and that SD before stroke, 
leading to sleep rebound in the acute phase of ischemia, is instead neuroprotective (Cam 
et al., 2013).  
In this study the main goal was to test the effects of pharmacological sleep 
promotion wih Bac starting 24 h after stroke onset, in order to avoid the reported 
neuroprotective effects of this compound (Jackson-Friedman et al., 1997, Zhang et al., 
2007). 
In accordance with the previous studies in rodents (Baumann et al., 2006, 
Leemburg, 2011), ischemic lesion resulted in a broad inhibition of the faster part of the 
EEG spectrum in the lesioned hemisphere. Bac administration following ischemia 
resulted in a significant increase in NREM sleep amount, particularly during the dark 
period. Bac given at the beginning of the light phase was less effective probably because 
of a ceiling effect. Furthermore, Bac led to a recovery of the power in the higher 
frequencies (above 8 Hz). Noteworthy, recent observations in rats, linked motor 
function recovery with EEG frequencies > 7 Hz (Leemburg, 2011, Zhang et al., 2013). 
SWA during NREM sleep has been associated with neuroplasticity processes (Tononi 
and Cirelli, 2006). Low-frequency synchronous neuronal activity has been suggested to 
have an important role in the anatomical reorganization and axonal sprouting after 
brain lesion (Carmichael and Chesselet, 2002). Therefore, the changes in EEG activity 
observed immediately after Bac injections could play a role in improving the functional 
outcome.  
In the present study cerebral ischemia was induced in the somatosensory cortex, 
thus leaving the motor cortical areas anatomically intact. Nevertheless, we observed a 
remarkable drop in the SPR performance after stroke. This effect was expected since 
motor cortex function was severely disrupted by extensive remodeling processes, 
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during the recovery period following ischemia even when the area itself is spared by the 
lesion (Gharbawie et al., 2005b). Spontaneous gradual improvement of motor function 
was present in the stroke animals injected with saline. However, Bac treatment 
accelerated performance improvement after stroke.  
After Bac treatment, we found increased BDA labeling in both, cortex and 
striatum, indicating an enhancement in the number of axons and/or increased axonal 
transport. Axonal sprouting, or the ability of brain to form new connections in areas 
denervated by the lesion, is a well-known phenomenon (Carmichael and Chesselet, 
2002, Wiessner et al., 2003). Ischemic damage of the sensorimotor cortex induced 
sprouting of axons into the peri-lesion cortex from the homotopic cortex in the 
contralateral hemisphere (Carmichael and Chesselet, 2002) and into the striatum below 
the lesion (Napieralski et al., 1996).  
Noteworthy, the corpus callosum atrophy was significantly reduced in Bac/isch 
group, despite the absence of the beneficial effect of Bac on the extent of brain damage. 
The atrophy of corpus callosum is a sensitive indicator of ischemic neuronal loss, since 
majority of the neurons projecting into the corpus callosum are highly vulnerable to 
ischemia pyramidal cells of cortical layers 3 and 4 (Yamauchi et al., 2000). Because 
corpus callosum is the conduit for the inter-hemispheric communication, its thickness 
might be a relevant factor influencing recovery of function after stroke. Our finding that 
Bac administration significantly reduced stroke-induced corpus callosum atrophy 
supplements the data showing a Bac-related boost in axonal sprouting.  
Repeated administration of Bac also boosted neurogenesis in the ischemic brain. 
We found an increase in the number of newborn cells. Several reports indicated that 
ischemic injury induces increased cell proliferation (Zhang et al., 2001b, Shin et al., 
2008), associated with migration of newborn cells to the lesion sites (Arvidsson et al., 
2002, Parent et al., 2002, Jin et al., 2003). However, only a small fraction of newborn 
cells display a long-term survival. Therefore, enhancement of endogenous neurogenesis, 
primarily by improving survival of newborn cells, would be a plausible strategy for 
restorative therapies. In our study BrdU was injected for 10 days after induction of 
ischemia, parallel with drug injection, and examined six weeks later. After extended 
periods, very few BrdU+ cells were found in the ipsilesional cortex, striatum and 
subventricular zone. In contrast, extensive BrdU staining was noted in the peri-infarct 
region in both ischemic groups. Peri-infarct area is critical for rehabilitation, it shows 
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intensified neuroplasticity, allowing remapping of sensorimotor function (Dijkhuizen et 
al., 2003, Cramer, 2008). Bac-treated rats had almost 2-fold increase in BrdU+ cells 55 
days after stroke onset. Hence Bac might not only increase cell proliferation, but also 
prolong survival of newborn cells and, therefore, enhance endogenous neurogenesis.  
Although the majority of newly formed cells found in the peri-infarct region 
expressed the neuronal marker NeuN, we also observed an increase in the number of 
proliferating cells expressing glial markers, GFAP (astrocytes) and Iba1 (microglia) after 
Bac treatment. Interestingly, the percentage of cells that differentiated into astrocytes 
was significantly higher in Bac/isch group, indicating that Bac might also affect 
differentiation of newborn cells. Glial cell activation has been demonstrated to 
accompany cerebral ischemia. However, there is a disagreement whether such gliosis is 
neuroprotective or harmful (Nedergaard and Dirnagl, 2005). Recent experimental 
evidence indicates that astrocytes and microglia play a dual role in tissue repair and 
reorganization (Swanson et al., 2004, Pekny and Nilsson, 2005, Ekdahl et al., 2009). 
Attenuation of reactive gliosis led to enlarged infarct volume, (Li et al., 2008), while 
enhanced survival of astrocytes by melatonin treatment after cerebral ischemia, 
conferred protection to the injured brain (Borlongan et al., 2000). Furthermore, 
defective microglial activation was associated with significant increase in the size of 
ischemic lesion and a 2-fold increase in the number of apoptotic neurons (Lalancette-
Hebert et al., 2012). The results of the present study are in accordance with the 
emerging view that glial cells are active participants in the maintenance of a functional 
central nervous system and play an important role in the recovery from the brain lesion.  
We observed that the increase in axonal sprouting and neurogenesis in Bac 
treated animals was positively correlated with the improvement of functional recovery 
in the SPR task during the 40 days period after stroke. Several studies have previously 
suggested an association between neuronal plasticity and neurological recovery. In 
experimental stroke, enhancement of axonal sprouting improves functional outcome 
after brain damage (Kawamata et al., 1997, Stroemer et al., 1998, Carmichael, 2008). In 
addition, disruption of neurogenesis impedes functional recovery after stroke, whereas 
treatment strategies aimed at augmenting neurogenesis are associated with functional 
improvement (Zhang et al., 2001a, Raber et al., 2004). We suggest that Bac treatment, 
most likely by promoting NREM sleep, enhanced endogenous mechanisms underlying 
neuronal plasticity and, therefore, improved functional recovery.  
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One intriguing finding of this study was that facilitation of functional recovery by 
Bac depended on the location of the lesion. Right hemisphere lesioned rats treated with 
Bac recovered faster, although the stroke extension/volume was similar on both sides. 
Brain asymmetry in motor and other functions was found in humans and rodents 
(Habib, 1989, Sullivan and Gratton, 1999). The biochemical and anatomical origin of 
lateralised behavioural responses remains however poorly understood.  
In summary, we have shown that an increase of NREM sleep induced by the 
delayed administration of baclofen promotes neuroplasticity and functional outcome in 
a rat model of stroke. Further studies are needed to understand the mechanisms 
responsible for these sleep-associated favourable effects.  
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5. GENERAL DISCUSSION  
 
Stroke is often referred to as the ‘silent killer’ because, unlike heart attack, it strikes 
without warning. Although acute ischemic stroke is a major problem, due to the 
continuous failure of compounds developed for its treatment, an effective therapy is 
lacking. Still, there is a great hope in this field. Recent data indicate that it might be 
possible to successfully treat a significant portion of stroke patients by promoting 
endogenous neuroplasticity. A big body of evidence demonstrates a remarkable ability 
of adult brain to reorganize and remap functional networks leading to recovery from 
stroke damage. One of the biggest experimental challenges in this field is to 
unequivocally link specific circuit changes with the improvement in behavioural 
outcomes observed during the recovery period. Thus, generation of animal models of 
ischemic brain lesion and investigation of new genetic tools, which could be applied, are 
currently of major interest. Mechanisms in which activity can scale down synaptic 
strength (that is, mechanisms that can induce homeostatic plasticity), such as sleep, can 
represent a big promise in humans.  
Clinical data have indicated sleep-wake disturbances as risk factors for the 
development of many neurological diseases, including ischemic stroke. Moreover, sleep 
disorders frequently occur in stroke patients and are related to worse recovery (Bassetti 
and Hermann, 2011). As previously introduced, experimental data indicated that sleep 
disruption after stroke aggravates brain damage and impairs recovery. If this conclusion 
is true, it could be assumed that an increase in sleep would have favourable effects on 
stroke outcome. Although sleep appears to facilitate neuronal plasticity in the healthy 
brain, its role in modulating the restorative process after brain injury is almost 
unknown. In these studies we manipulated sleep by means of a pharmacological 
approach in a rat model of focal cerebral ischemia. The results obtained in this thesis, 
not only support the close relationship between brain plasticity, stroke outcome and 
sleep, but also identify sleep as a tool to improve brain recovery from neuronal damage. 
This could lead to development of a possible sleep-modulating treatment to improve 
stroke outcomes. 
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5.1 Bac and GHB effects on sleep 
 
In the first study, we aimed to check whether and how Bac and GHB affected sleep in 
healthy rats.  
There is a big body of evidence that GABA plays a major role in sleep regulation 
(Gottesmann, 2002). A prominent role of GABAA receptors in sleep, in particular the 
pharmacological management of disturbed sleep has been established (Winsky-
Sommerer, 2009). GABAA receptor agonists and different compounds interacting with 
the GABAA receptor complex, such as barbiturates and benzodiazepines, can interfere 
with the sleep/wake cycle (Sieghart, 1995). On the other side, there is still little 
information about the importance of GABAB receptors in sleep modulation and EEG 
changes. They have been reported to be important in several conditions, such as 
epilepsy (Schuler et al., 2001), anxiety and depression (Mombereau et al., 2004), 
nociception (Zarrindast et al., 2000), memory (Levin et al., 2004), addiction (Cruz et al., 
2004, Filip and Frankowska, 2008) and potentially sleep (Juhasz et al., 1994, Ulloor et al., 
2004). Both, Bac and GHB are ligands of GABAB receptors. Of importance, both of the 
drugs are currently in clinical use, Bac to treat spasticity (Albright et al., 1991, Paisley et 
al., 2002, Bensmail et al., 2006), while GHB sleep disturbances associated with 
narcolepsy (Billiard et al., 2006). 
The main findings of this investigation were that in rats, Bac and GHB had a 
strong effect on behaviour, vigilance states and EEG pattern. Most importantly and 
relevant for our consecutive project, Bac but not GHB, had sleep-promoting properties. 
In addition, our study was the first to evaluate the effects of Bac and GHB given at two 
circadian time points, which are associated with different sleep pressure. We found clear 
differences in the effect on sleep of both substances regarding light-dark cycle. Drugs 
given at the beginning of the dark period, coinciding with the daily activity phase of rats, 
revealed more pronounced effects on sleep. Sleep-wake behaviour of rats during the 
dark period is often used as a physiological model for insomnia in humans and is more 
sensitive to the hypnotic effects of drugs (Lancel and Langebartels, 2000). Hence, with 
this study we highlight also the importance of considering the changes in endogenous 
sleep and the different drug’s kinetics according to the circadian phase, while applying 
different agents in experimental and therapeutic conditions. Furthermore, changes in 
EEG power spectra during waking, NREM and REM sleep observed in our study might be 
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related to the complex mechanisms, engaging multiple mutually cooperating 
neurotransmitter systems. Presently, there is a lot of effort to create drugs acting 
through GABA receptors in order to promote physiological sleep for therapeutic 
purposes. Further elaborate research is needed to better understand drug mechanism of 
action and adverse effects on physiology.  
 
 
5.2 Sleep promotion and stroke outcome 
 
While sleep disruption in the acute phase after stroke has been shown to have 
detrimental effects in both humans and animals, the effect of sleep promotion remains 
unclear. To gain insight into this question we promoted sleep with Bac, starting at 24 h 
after stroke. In this study we showed that repeated treatment with Bac after focal 
cerebral ischemia in rats improved long-term functional recovery accompanied by 
enhanced endogenous brain repairing mechanisms, such as axonal sprouting and 
neurogenesis. These beneficial effects of Bac on stroke outcome might be mediated by 
sleep. 
 
Bac, sleep and neuroplasticity 
We propose that the positive effects of Bac on axonal sprouting and neurogenesis after 
cerebral ischemia were related to sleep-induced mechanisms. Axonal sprouting after 
stroke is regulated by various neuroplasticity-related genes, including growth-
promoting and growth-inhibiting molecules (Carmichael et al., 2005). Many of these 
genes and proteins associated with neuroplasticity have been shown to be modulated by 
sleep (Cirelli et al., 2004, Basheer et al., 2005). Previous studies showed that sleep 
deprivation after stroke induced an increase in the expression of neurocan (the main 
growth-inhibiting molecule to axonal sprouting) (Gao et al., 2010), while GHB decreased 
it (Gao et al., 2008). Therefore, changes in sleep may affect molecules crucial for post-
stroke axonal sprouting. Furthermore, Carmichael et al. demonstrated the strong 
correlation between axonal sprouting and the periodic synchronized neuronal activity, 
the same type of activity that is known to be important during development of axonal 
projections (Carmichael and Chesselet, 2002). They suggested that this rhythmic activity 
is an initial trigger critical for induction and maintenance of axonal sprouting after 
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ischemic lesion. In the present study, Bac, besides its effects on sleep, also induced a 
transient electrophysiological hypersynchronous pattern during the sub-anaesthetic 
state, which could play a role in axonal growth and functional outcome.  
Neurogenesis has been shown to be reduced after several days of sleep 
deprivation or sleep disruption in healthy rats (Guzman-Marin et al., 2005, Meerlo et al., 
2009). Consistent with these results, our previous studies demonstrated that rats 
subjected to sleep deprivation during the acute and sub-acute phase of  ischemic stroke 
revealed a substantial reduction in the number of proliferating cells (Zunzunegui et al., 
2011). These findings imply that mechanisms associated with sleep may promote 
production of new cells. In other words: if on the one side sleep deprivation reduces 
neurogenesis, would sleep promotion facilitate it? At present, there is no direct proof 
that sleep promotes production of new cells directly, however it may be essential for 
normal functioning of other processes that regulate neurogenesis. In this study, several 
mechanisms could account for the increase in neurogenesis after stroke. Neurogenesis is 
regulated and affected by a wide variety of trophic factors, cytokines, hormones, 
neuromodulators and neurotransmitters (Abrous et al., 2005, Hagg, 2005) that are also 
altered by sleep loss. Furthermore, sleep has been suggested to be necessary for the 
anabolic process underlying cell proliferation (Guzman-Marin et al., 2005). The release 
of anabolic hormones is modulated by sleep, e.g. the release of growth hormone (GH) is 
associated with SWA in humans (Parker et al., 1969) and rats (Kimura and Tsai, 1984). 
Sustained sleep deprivation in rats reduced levels of GH and its mediator, insulin-like 
growth factor (IGF)-1 (Everson and Crowley, 2004), known to promote neurogenesis 
(Aberg et al., 2000). Several studies indicated that overall brain protein synthesis rate 
required for cell proliferation is increased in NREM sleep (particularly deep NREM 
sleep) in primates (Nakanishi et al., 1997) and rats (Ramm and Smith, 1990), compared 
with waking or REM sleep. Here we show that Bac resulted in prominent increase of 
NREM sleep amount after stroke, implying facilitating role of sleep in neuroplastic 
changes. In this frame of reference, our results suggest that Bac-stimulated cell 
proliferation induced by stroke could have been mediated by sleep-related mechanisms. 
In addition to the increase in the number of newborn neurons, Bac enhanced also 
the amount of proliferating astrocytes and microglia. There is increasing evidence 
suggesting that glial cells not only play a supportive role for neuronal activity but also 
have an essential roles in brain plasticity (Todd et al., 2006, Pekny et al., 2007, Ota et al., 
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2013, Welberg, 2014). Astrocytes are responsible for regulating the synaptic 
environment and for maintaining appropriate levels of neurotransmitters and 
neurotrophins. They influence neuronal signalling, the number of synapses and play a 
role in non-synaptic transmission (Vernadakis, 1996, Chvatal and Sykova, 2000, Ullian et 
al., 2001). Microglia, beyond its role as the brain’s resident immune cells, have various 
different functions including playing a critical role during brain development (Derecki 
and Kipnis, 2013, Zhan et al., 2014). The role of glial cells in neuronal death has become 
a major research interest during last years. Although a lot of controversy exists about 
function of glial cells in cerebral ischemia, a solid evidence indicates that they have an 
active and protective role in the pathophysiology of ischemic injury (Borlongan et al., 
2000, Nedergaard and Dirnagl, 2005, Lalancette-Hebert et al., 2007, Lalancette-Hebert et 
al., 2012). The results of our study support the notion that glial cells are equally active 
participants as neurons in the maintenance of a functional central nervous system and 
are closely involved in the brain injury. Therefore, modulation of glial cells activity, aside 
neurons, may be a promising future target for therapeutic interventions promoting 
regeneration and plasticity in the brain after various injuries. 
 
Asymmetric effect of lesion on recovery 
One of the most intriguing findings of our study was the asymmetric effect of lesion on 
the degree of functional recovery. The detailed data analysis demonstrated that 
facilitation of functional recovery by Bac depended on the location of brain lesion. 
Although cerebral functional asymmetry in animals is still an underappreciated 
phenomenon, it is not anymore considered as an unique feature of the human brain - the 
leading concept for many years (Levy, 1977). Brain asymmetry has been extensively 
investigated in humans and rodents (Habib, 1989, Sullivan and Gratton, 1999), however 
the biochemical and anatomical origin of lateralised behavioural response has not been 
precisely understood yet.  
There are several mechanisms that could account for the effects observed in the 
present study. One of the possible explanations is that the course of spontaneous 
recovery has been reported to be worse after lesions in the right, compared to the 
lesions in the left hemisphere (Miklyaeva et al., 1993). The reported behavioural 
asymmetry after stroke in our study is consistent with these findings. Hence, the 
difference between Bac and saline-treated animals after the right-side injury could 
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result from the poorer spontaneous recovery, allowing the drug to reveal its efficacy. It 
is important to mention here that the size of the damage could not be the reason of the 
observed asymmetry, because the mean volume of the right and left hemispheric lesions 
were not different. Another possible explanation could be that this lateralised recovery 
promoted by Bac was the consequence of neuroanatomical or chemical asymmetries in 
the brain. It was shown that only right cortical or subcortical lesions led to the 
lateralised behavioural response and this effect was related to biochemical changes 
generated by the lesion (Robinson and Coyle, 1980, Robinson and Justice, 1986, 
Starkstein et al., 1988). Numerous studies demonstrated left/right hemispheric 
asymmetries in the mesocortical dopamine (DA) projections (Slopsema et al., 1982, 
Carlson et al., 1993), which originate in the ventral tegmental area (VTA) and provide 
modulatory input to the frontal cortex. In addition, differential sensitivity of the two 
hemispheres to neurotoxic destruction of noradrenergic (NE) terminals was reported 
(Robinson and Justice, 1986). Furthermore, asymmetry of the sympathetic nervous 
system has been shown to be partially involved in the lateralised immune responses 
(Neveu, 1992). Rats submitted to the right hemisphere lesion had greater sympathetic 
consequences (e.g. increase in NE plasma level) (Hachinski et al., 1992) and higher 
immune reactivity (Renoux et al., 1983) than the left-lesioned rats. Interestingly, Bac is 
known to affect both DA neurons in VTA (Cruz et al., 2004) and NE neurons in locus 
coeruleus (LC) (Osmanovic and Shefner, 1988). In addition, recent evidence has 
suggested its anti-inflammatory role (Duthey et al., 2010). Therefore, if DA and NA 
activity level is changed only after right-side lesion, and Bac is known to affect both DA 
in VTA (Cruz et al., 2004) and NA in LC (Osmanovic and Shefner, 1988) , it might be that 
the pronounced effect of Bac in right-lesioned rats is caused by normalization of the 
balance disturbed by stroke. However, the mechanisms underlying the physiological 
cortico-subcortical and autonomic interactions dependent on the side of the lesion, 
remains to be elucidated.  
Identification of lateralised behavioural and biochemical response to the brain 
injury in rats may have important clinical implications. The evidence that patients with 
damage in the left frontal brain area exhibit symptoms of major depression and 
catastrophic reactions more frequently, while patients with the right hemispheric injury 
have greater incidence of inappropriate cheerfulness and apathy, may be explained as an 
  
75 
emotional manifestation of differential biochemical response of the human brain to 
injury (Robinson et al., 1984).   
Concomitantly with asymmetry in functional improvement, we noted also 
lateralization in axonal sprouting and neurogenesis. Thus, ischemic animals 
administered with saline, revealed greater corticocortical projections and the number of 
newborn neurons and astrocytes, after lesion in the left hemisphere relative to these in 
the right hemisphere (data not shown). Consequently, the endogenous neuroplasticity 
was decreased in the right-lesioned rats, whose course of the spontaneous recovery was 
worse. Although the sample size was too small to conduct appropriate statistical 
analysis, it would be another proof of association between brain plasticity and 
neurological recovery. Nevertheless, future work should investigate this enthralling 
question more systematically. 
 
 
5.3 Outlook 
 
In summary, this thesis provides an excellent basis to further investigate the 
involvement of sleep in the process of stroke recovery. Based on these results we 
suggest that sleep promotion after stroke leads to the improvement in stroke outcome. 
We propose that sleep enhancement by Bac leads to neuroplastic changes, that in turn 
trigger functional recovery. However, future work needs to prove this hypothesis by 
identifying specific cellular mechanisms. One way to do so would be to carry out further 
experiments characterising sleep-mediated pathways involved in stroke 
pathophysiology and molecular mechanisms that underlie brain repair. In this context, 
screening gene expression at a large scale would be necessary to pursue the 
investigation of molecular candidates that mediate the sleep-mediated changes in brain 
restorative processes.   
In the present study we evaluated only Bac as an effective sleep-promoting drug. 
That was based on the results from the first experiments, which did not reveal sleep- 
promoting effects of another tested drug, GHB. However, it could be that GHB injected 
repeatedly, for longer time period, with higher dose would also show positive action. 
Therefore, it would be appealing to evaluate whether GHB and/or other sleep-
promoting drugs, such as for example tiagabine, GABA uptake inhibitor or THIP (4,5,6,7-
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Tetrahydroisoxazolo[4,5-c]pyridin-3-ol), GABAA receptor agonist, could have similar 
effects.  
In the study presented here the EEG recordings were performed only until the 
day 12th after injury, i.e. the last day of the drugs’ administration. This duration could 
have been too short to observe any big changes in the EEG spectral power. It would be 
interesting to evaluate EEG parameters at a later phase during recovery process, after 
the end of the drug treatment period. It could be that possible alterations in EEG spectra 
occurring during this later phase, after drug treatment, have an essential role for brain 
plasticity. Moreover, further investigation of the role of EEG activity in functional 
recovery would require a finer array of electrodes allowing direct measurements of 
synchrony and functional connectivity within the motor cortex. Next, we only evaluated 
spectral power during NREM sleep. Since other vigilance states may also be affected by 
Bac treatment and important for recovery process, it would be important to analyse the 
waking and REM sleep spectra as well.  
These findings have a potentially important impact on our understanding of brain 
restorative processes after damage and deserve further investigation at the molecular, 
cellular and systemic level. Specifying the role of sleep in brain repair mechanisms will 
undoubtedly pose a particular challenge for future research. 
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6. LIST OF ABBREVIATIONS 
 
AMPA,  α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Bac,  baclofen 
BDA,  biotinylated dextran amine 
BDNF,  brain-derived neurotrophic factor  
BL,  baseline 
BrdU, 5-bromo-2′-deoxyuridine 
CCA,  common carotid artery 
DA,  dopamine 
EEG,  electroencephalogram 
EMG,  electromyogram 
GABA,  gamma-aminobutyric acid 
GH,  growth hormone 
GHB,  gamma-hydroxybutyric acid 
IGF-1,  insulin-like growth factor 1 
i.p.,  intraperitoneal   
isch,  ischemia 
LC,  locus coeruleus 
LTD,  long-term depression 
LTP,  long-term potentiation 
MCA,  middle cerebral artery 
MRN,  median raphe nucleus 
NE,  noradrenaline 
NREM,  non-rapid eye movement 
PBS,  phosphate buffered saline 
PFA,  paraformaldehyde 
REM,  rapid eye movement 
rt-PA,  recombinant tissue plasminogen activator 
SD,  sleep deprivation 
SDis,  sleep disturbances 
SPR,  single pellet reaching 
SWA,  slow-wave activity 
SWS,  slow-wave sleep    
tDCS,  transcranial direct current stimulation    
THIP,  4,5,6,7-Tetrahydroisoxazolo[4,5-c]pyridin-3-ol 
TMS,  transcranial magnetic stimulation 
VTA,  ventral tegmental area 
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"The impossible missions are the only ones to succeed."  
(Jacques Cousteau) 
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